

# Adenovirus

Joseph P. Lynch, III, M.D.,<sup>1</sup> Michael Fishbein, M.D.,<sup>2</sup> and Marcela Echavarria, Ph.D.<sup>3</sup>

## ABSTRACT

Adenoviruses (AdV) are DNA viruses that typically cause mild infections involving the upper or lower respiratory tract, gastrointestinal (GI) tract, or conjunctiva. Rare manifestations of AdV infections include hemorrhagic cystitis, hepatitis, hemorrhagic colitis, pancreatitis, nephritis, or encephalitis. Adenovirus infections are more common in young children, owing to lack of humoral immunity. Epidemics of AdV infections may occur in healthy children or adults in closed or crowded settings (particularly military recruits). The disease is more severe, and dissemination is more likely in patients with impaired immunity (eg, organ transplant recipients, human immunodeficiency virus infection, congenital immunodeficiency syndromes). Fatality rates for untreated severe AdV pneumonia or disseminated disease may exceed 50%. More than 50 serotypes of AdV have been identified. Different serotypes display different tissue tropisms and correlate with clinical manifestations of infection. The predominant serotypes differ among countries or regions and change over time. Transmission of novel strains between countries or across continents and replacement of dominant serotypes by new strains may occur. Treatment of AdV infections is controversial because prospective, randomized therapeutic trials have not been done. Cidofovir is considered the drug of choice for severe AdV infections, but not all patients require treatment. Vaccines have been shown to be highly efficacious in reducing the risk of respiratory AdV infection but are currently not available.

**KEYWORDS:** Adenovirus, respiratory viral infection, serotypes, cidofovir

## ADENOVIRUS (AdV)

Adenovirus (AdV) infections most often involve the upper or lower respiratory tract, pharynx, conjunctiva, or gastrointestinal (GI) tract.<sup>1,2</sup> More than 80% of AdV infections occur in children <4 years old (due to lack of humoral immunity).<sup>1-5</sup> Immunosuppressed persons<sup>1,3,6,7</sup> are also more susceptible.<sup>2,8-11</sup> High baseline immunity against AdV (titer of  $\geq 1:32$ ) con-

fers substantial protection.<sup>12</sup> Epidemics of AdV infections may occur in healthy children<sup>2,8-11</sup> or adults in closed or crowded settings (particularly military recruits).<sup>13-17</sup> The vast majority of cases are self-limited. However, the clinical spectrum is broad, and dissemination or pneumonia can be fatal, in both immunocompetent<sup>18,19</sup> and immunocompromised patients.<sup>1,3,20-24</sup>

<sup>1</sup>Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology, Department of Internal Medicine, The David Geffen School of Medicine at UCLA, Los Angeles, California; <sup>2</sup>Department of Pathology and Laboratory Medicine, The David Geffen School of Medicine at UCLA, Los Angeles, California; <sup>3</sup>Clinical Virology Laboratory, Centro de Educacion Medica e Investigaciones Clinicas (CEMIC) University Hospital, Buenos Aires, Argentina.

Address for correspondence and reprint requests: Joseph P. Lynch, III, M.D., Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology, The David Geffen School of Medicine at

UCLA, 10833 Le Conte Ave., Rm. CHS 37-131, Los Angeles, CA 90095 (e-mail: jplynch@mednet.ucla.edu).

Respiratory Viral Infections; Guest Editors, Adriana Weinberg, M.D. and Martin R. Zamora, M.D.

Semin Respir Crit Care Med 2011;32:494-511. Copyright © 2011 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

DOI: <http://dx.doi.org/10.1055/s-0031-1283287>.

ISSN 1069-3424.

## Virology

Human AdV is a family of double-stranded, nonenveloped DNA viruses belonging to the genus *Mastadenovirus* of the Adenoviridae family.<sup>25,26</sup> Fifty-two serotypes and seven species (A through G) are recognized.<sup>27–29</sup> New candidates are recognized,<sup>30</sup> but their classification is still under discussion. The use of phylogenetic analysis as the sole means of classifying a new serotype is controversial. Species A, B, C, D, and E circulate globally and have been implicated in outbreaks of infections in humans.<sup>20</sup> However, more than half of AdV serotypes are infrequently detected,<sup>20</sup> and only one third of serotypes are associated with human disease.<sup>22,25,27,30–33</sup> Different serotypes display different tissue tropisms and correlate with clinical manifestations of infection<sup>1,22,27,29</sup> (discussed in detail later).

## Epidemiology

AdVs may cause epidemics of febrile respiratory infections (FRIs), pharyngoconjunctival fever,<sup>34</sup> keratoconjunctivitis (KC),<sup>35–38</sup> or gastroenteritis and diarrheal illness.<sup>39–50</sup> Severe or disseminated AdV infections may occur in patients with impaired immunity<sup>6</sup> [eg, organ transplant recipients<sup>3</sup>; human immunodeficiency virus (HIV) infection<sup>51</sup>; congenital or combined immunodeficiency syndromes<sup>52,53</sup>] and rarely in immunocompetent patients.<sup>19,54</sup>

Infection can be by reactivation, exposure to infected individuals, or new acquisition from exogenous sources.<sup>1,22</sup> Infections occur throughout the year,<sup>1</sup> but most epidemics occur in the winter or early spring.<sup>5</sup> Latent AdV may reside in lymphoid tissue,<sup>6,55</sup> renal parenchyma,<sup>56</sup> or other tissues after childhood inoculation; reactivation may occur in severely immunosuppressed patients.<sup>6,55,56</sup> Importantly, *asymptomatic* carriage of AdV may persist for weeks or months.<sup>27,57,58</sup> Transmission of AdV can occur via inhalation of aerosolized droplets, direct conjunctival inoculation, fecal-oral spread, exposure to infected tissue or blood,<sup>1,59,60</sup> or environmental surfaces (eg, linen, pillows, lockers, guns).<sup>61,62</sup> The incubation period ranges from 2 to 14 days and depends upon viral serotype and mechanism of transmission.<sup>1</sup> Epidemics may spread rapidly among closed populations, for example, among military recruits<sup>12,13,16,29,33,61,63–65</sup> and in hospitals,<sup>5,60,66,67</sup> neonatal nurseries,<sup>66</sup> psychiatric<sup>67,68</sup> or long-term care facilities (LTCFs),<sup>37,59,69</sup> job training centers,<sup>17</sup> boarding schools or dormitories,<sup>70</sup> a children's home,<sup>71</sup> orphanages,<sup>72</sup> public swimming pools,<sup>73,74</sup> and so forth. Crowding and poor hygienic behaviors may facilitate spread.<sup>67</sup> In institutionalized settings, infection control measures and cohorting may be essential to limit spread.<sup>59,60,75</sup> AdV lacks an envelope and is thus resistant to many disinfectants.<sup>76</sup> Alcoholic (95% ethanol) solution is an effective disinfectant.<sup>58</sup>


## CLINICAL FEATURES OF ADENOVIRUS INFECTION

### Respiratory Tract Involvement

AdV accounts for at least 5 to 10% of pediatric and 1 to 7% of adult respiratory tract infections (RTIs).<sup>1,27</sup> In immunocompetent patients (children or adults), symptoms abate spontaneously (within 2 weeks) and induce type-specific immunity.<sup>1</sup> Fever, pharyngitis, tonsillitis, cough, and sore throat are common symptoms in children and young adults with AdV RTI.<sup>2,15</sup> GI symptoms may manifest concomitantly.<sup>2,15</sup> In a study of 317 hospitalized children with acute AdV RTI in Taiwan, GI symptoms included diarrhea (25%), vomiting (22%), and abdominal pain (19%).<sup>11</sup> Another study in Korean children with RTIs cited the following GI symptoms: diarrhea (31%), vomiting (20%), and abdominal pain (4%).<sup>77</sup> Pneumonia occurs in up to 20% of young children (particularly in newborns and infants)<sup>2,8,10,77</sup> but is uncommon in immunocompetent adults.<sup>1,12,13,67,68,78</sup> However, fatalities due to AdV pneumonia (sometimes associated with septic shock) have been described in previously healthy children<sup>8</sup> or adults.<sup>15,19,54,68</sup> Meningitis is a rare complication of AdV pneumonia.<sup>78</sup> In immunocompromised persons, dissemination and/or severe respiratory failure may develop in 10 to 30% of cases.<sup>1,3,23,79</sup> Fatality rates for severe AdV pneumonia may exceed 50%<sup>1,3,78</sup> (Fig. 1). In children, long-term respiratory sequelae of AdV RTI include bronchiectasis, bronchiolitis obliterans, and hyperlucent lung.<sup>80,81</sup>

### Keratoconjunctivitis

Adenoviral keratoconjunctivitis is a major cause of ocular morbidity and can lead to visual loss.<sup>82,83</sup> Manifestations of ocular AdV infection include epidemic keratoconjunctivitis (EKC), pharyngoconjunctival fever, and non-specific conjunctivitis.<sup>38,84–86</sup> The most common serotypes associated with EKC are AdV-8, 19, 37, and 5,<sup>38,82,83,85,87–90</sup> but other serotypes (eg, AdV-3, 4, 7, 11, and 14) can cause conjunctivitis.<sup>35,36,82,83,88,91,92</sup> In Taiwan, AdV-8, 19, and 37 were the predominant causes of AdV EKC.<sup>87</sup> AdV-8 predominated from 1980 to 1994; after 1995, AdV-37 and AdV-19 predominated and AdV-8 disappeared.<sup>87</sup> Outbreaks of EKC can occur in chronic care facilities,<sup>59,93</sup> hospitals or outpatient clinics,<sup>84,85,94</sup> and closed settings.<sup>95</sup> In one chronic care facility, 47 of 95 residents developed EKC due to AdV-37 between September 14 and December 1990 (attack rate 49%).<sup>59</sup> The outbreak was successfully interrupted following strict infection control, cohorting, suspension of new admissions, and changing to a disinfectant that inactivated AdV. Nosocomial transmission has been noted in eye clinics or hospitals via environmental contamination (ophthalmic instruments, eyedrops).<sup>85,94</sup>



**Figure 1** Fatal case of adenovirus pneumonia. (A) Gross lung with pale, consolidated region, C. (B) Histopathology showing hemorrhagic necrotic lung tissue [hematoxylin and eosin (H&E) stain,  $\times 40$ ]; (C) High magnification showing three cells with intranuclear inclusions (arrow) (H&E,  $\times 400$ ). (D) Immunohistochemical staining for adenovirus showing positive staining of the intranuclear inclusions in two cells (arrow) (immunoperoxidase,  $\times 400$ ).

Rigorous sterilization of instruments and infection control were essential to curb epidemics.<sup>85,94</sup>

### Gastrointestinal Manifestations

AdV infections can cause GI symptoms even when the primary site of involvement is the respiratory tract

(particularly in young children).<sup>2,11,77</sup> However, some serotypes (notably AdV-40 and 41) have an affinity for the GI tract,<sup>39,42,43,46</sup> with predominant symptoms of gastroenteritis or diarrhea.<sup>96</sup> Rare complications include hemorrhagic colitis,<sup>1,23</sup> hepatitis,<sup>23,97,98</sup> cholecystitis,<sup>99</sup> and pancreatitis.<sup>100</sup>

### Urinary Tract Involvement

AdV may cause urinary tract infections (UTIs),<sup>101</sup> particularly among hematopoietic stem cell transplant (HSCT)<sup>56,102–105</sup> and solid organ transplant (SOT) recipients.<sup>106–109</sup> Typical manifestations include dysuria, hematuria, hemorrhagic cystitis (HC), and renal allograft dysfunction.<sup>107,108,110</sup> Renal biopsies may reveal viral nephropathy<sup>111,112</sup> or (in the context of renal transplant recipients) allograft rejection.<sup>108</sup> Most AdV UTIs (including HC) are self-limiting.<sup>32,56,106,110</sup> However, necrotizing tubulointerstitial nephritis,<sup>112,113</sup> fatal or dialysis-dependent renal failure,<sup>111,112,114</sup> obstructive uropathy,<sup>113</sup> and fatal dissemination<sup>115,116</sup> may occur. Most common serotypes associated with HC include AdV-11, 34, 35, 3, 7, and 21.<sup>1,108,110,112</sup> The diagnosis is often made by culture, or polymerase chain reaction (PCR) in urine, or serology.<sup>1,103,108</sup> Renal biopsy may demonstrate viral infection of tubular epithelial cells with “smudge cells” and intranuclear inclusions.<sup>111,112</sup>

### Disseminated Disease

Disseminated AdV infections are rare among immunocompetent hosts, but dissemination occurs in 10 to 30% of HSCT recipients with AdV infection.<sup>1,3,21,22,79,117–119</sup> Diagnosis is made by PCR in blood<sup>116</sup> or recovery of AdV from more than one site. Among HSCT recipients with *symptomatic* AdV disease, fatality rates range from 12 to 70%<sup>1,3,21,117,120–122</sup>. Case fatality rates for AdV pneumonia may exceed 50%.<sup>1,3,23,78</sup>

### Rare Manifestations

Rare manifestations of AdV infections include myocarditis and cardiomyopathy,<sup>123</sup> encephalitis,<sup>124–126</sup> mononucleosis-like syndromes,<sup>127</sup> pulmonary dysplasia,<sup>128</sup> intestinal intussusception in children,<sup>129</sup> and sudden infant death.<sup>130</sup>

## SPECIFIC PATIENT POPULATIONS AT RISK

### Adenovirus Infections in Immunocompetent Persons

Epidemics of AdV respiratory infections may occur in healthy children (particularly  $<4$  years old)<sup>2,8–11</sup> or adults in closed settings (particularly the military).<sup>13,15–17</sup> The vast majority of cases are self-limited;

disseminated and fatal infections are rare in immunocompetent hosts.<sup>15,78</sup>

### Adenovirus Infections in Military Recruits

Outbreaks of AdV FRIs among military recruits elucidated the molecular epidemiology and dynamics of transmission of AdV.<sup>12,13,29,61,62</sup> Acute FRI due to AdV is a major cause of morbidity in the military, not only in the United States<sup>15,63,64</sup> but globally.<sup>33,65</sup> Military recruits are especially vulnerable, owing to crowding and stresses associated with the basic training environment.<sup>15</sup> The affected (military) population is highly mobile. Following completion of basic training, recruits are dispersed to secondary sites for advanced training, paving the way for epidemic spread.<sup>75</sup> Peak illness rates occur during weeks 3 through 5 of training.<sup>16</sup> AdV accounts for >50% of FRIs and 90% of pneumonia cases among healthy military recruits.<sup>12,13,15,16</sup> In a prospective study of 271 new military recruits in training, 25% developed an acute FRI due to AdV-4 over a 6-week period; all FRIs occurred among recruits with an initial AdV titer of <1:4.<sup>62</sup> Serum antibodies to AdV-4 were present in 34% at enrollment and climbed to 97% by 6 weeks.<sup>62</sup> Historically, serotypes AdV-7 and 4 predominated as a cause of FRIs in the U.S. military.<sup>12,13,63</sup> Beginning in 1971, all recruits in the U.S. military were vaccinated with live enteric-coated AdV-4 and AdV-7 vaccines.<sup>131</sup> Following this strategy, the incidence of AdV infections in the military setting fell substantially.<sup>131</sup> Unfortunately, in 1995 the sole manufacturer of the AdV vaccines ceased production; existing supplies were completely depleted by 1999.<sup>15</sup> The lack of availability of vaccines led to reemergence of epidemics of AdV infections in military facilities (all services).<sup>15,16,63,64,132-134</sup> Surveillance of U.S. recruits in training from 1999 to 2004 cited >73,000 AdV infections; during that time frame, serotype 4 accounted for >95% of AdV infections.<sup>16</sup> The epidemic of infections resulted from spread of AdV-4 from an army basic training site to secondary sites.<sup>64</sup> In 1997, an epidemic (> 500 cases) of AdV FRIs in the navy's sole basic training center in the United States was attributed to serotypes AdV-7 (70%) and AdV-3 (24%), respectively.<sup>15</sup> In 2006 and 2007, a novel strain of AdV-14 emerged as a cause of FRIs in recruits at a U.S. Air Force base<sup>29</sup> and has become the predominant strain in the military.

### Hematopoietic Stem Cell Transplant Recipients

The reported incidence of AdV infections is highly variable (3 to 47%) among HSCT recipients.<sup>1,3,21-24,31,117-120,135-137</sup> The lower range (3%) was observed when systematic screening was not performed,<sup>137</sup> whereas higher rates reflect prospective studies with

regular sampling of plasma for AdV DNA (by PCR).<sup>117,138</sup> The incidence is 2 to 3.5 times higher in children (>20%) compared with <10% in adults.<sup>79,136,137,139,140</sup> Additional risk factors for AdV infections among HSCT recipients include allogeneic HSCT,<sup>79,137</sup> HLA (human leukocyte antigen) mismatch,<sup>79,141</sup> severe T cell depletion,<sup>24,79</sup> and graft versus host disease (GVHD).<sup>1,21,23,24,117,118,120,137</sup> Infection can reflect primary infection (eg, community or nosocomial acquisition)<sup>58</sup> or reactivation of latent infection.<sup>3,55,58</sup>

Serotypes most commonly cited among organ transplant recipients include species C (AdV-1, 2, 5), species A (AdV-31), and species B (AdV-11, 34, 35).<sup>40,116,135</sup>

AdV in HSCT recipients is usually detected within 100 days of the transplant.<sup>79</sup> Clinical manifestations range from mild, self-limited disease to fatal dissemination.<sup>79</sup> In most patients, the disease is localized (eg, urinary tract, gastroenteritis, upper or lower respiratory tract infections) but dissemination occurs in 10 to 30% of cases.<sup>24,79,136,139</sup> In this context, mortality rates are high.<sup>79</sup> Among 76 adult HSCT recipients with *symptomatic* AdV infections the mortality rate was 26%.<sup>137</sup> Mortality rates were higher among patients with pneumonia (73%) and disseminated disease (61%). Severe lymphopenia,<sup>1,79</sup> severe GVHD,<sup>24,137</sup> isolation from more than one site,<sup>79</sup> and high AdV viral loads in plasma<sup>142,143</sup> correlate with higher mortality. However, the prognosis may be good, particularly when the viral load is low. A retrospective study in pediatric HSCT recipients detected AdV in blood (by PCR) in 11/26 (42%); viremia cleared in seven (63%) without antiviral therapy.<sup>32</sup> Quantification of AdV DNA load by real-time PCR in plasma of HSCT recipients may identify patients at high risk for dissemination<sup>139,142</sup> or assess response to therapy.<sup>139,142</sup> Although indications and efficacy of therapy are controversial, cidofovir (CDV) was associated with a low mortality rate (2%) in pediatric HSCT recipients with AdV infections.<sup>138</sup> In that study, clinical and microbiological cure was achieved in 56/57 patients.<sup>138</sup>

### Solid Organ Transplant Recipients

The incidence of AdV infections is 5 to 22% among SOT recipients.<sup>1,79,120,144</sup> AdV infections have been noted in liver,<sup>145,146</sup> renal,<sup>108,114,147</sup> intestinal,<sup>148</sup> heart,<sup>144</sup> and lung<sup>149</sup> transplant recipients (primarily in children). Among SOT recipients, risk factors for AdV include pediatric age,<sup>79,145</sup> receipt of antilymphocyte antibodies,<sup>79</sup> and donor-positive/recipient-negative AdV status.<sup>79</sup> In a prospective study, PCR detected AdV viremia within 12 months of transplant in 19/263 (7.3%) SOT recipients, including liver 10/121 (8.3%), kidney 6/92 (6.5%), and heart 3/45 (6.7%).<sup>144</sup> At the time of viremia, 11 (58%) were asymptomatic. All recovered spontaneously without sequelae. In a retrospective

review of 484 pediatric liver transplant recipients, 49 (10%) developed AdV infections; nine died of invasive AdV infection.<sup>145</sup> In another retrospective review of 191 adult liver transplant recipients, 11 (5.8%) had AdV infection associated with two deaths.<sup>146</sup> Clinical manifestations of AdV infection are protean, but the primary site of disease in SOT recipients is often related to the transplanted organ.<sup>79</sup> In liver transplant recipients, AdV typically causes jaundice, hepatomegaly, and hepatitis.<sup>79</sup> In renal transplant patients, the principal symptom is HC; further, AdV may target the renal allograft, leading to graft failure.<sup>108,114,147</sup> In pediatric heart transplant recipients, the presence of AdV in posttransplant endomyocardial biopsies increased the risk for graft loss and posttransplant coronary artery disease.<sup>150–152</sup> Only four cases of AdV infections were identified in a cohort of 383 lung transplant recipients (LTRs) (1.3%); incidence was 3/40 (8%) among pediatric LTRs and 1/268 (0.4%) among adult LTRs. However, all four developed severe hemorrhagic, necrotizing AdV pneumonia; all died within 45 days of the transplant.<sup>149</sup> In a study of 19 pediatric LTRs, AdV was detected in eight, resulting in two early deaths as well as late graft loss and obliterative bronchiolitis.<sup>147</sup> A case of fatal AdV pneumonia in an adult LTR 4 years posttransplant was described.<sup>153</sup> Although these studies underscore the potential for AdV to cause severe, even fatal, infections in SOT recipients, routine PCR surveillance in adult SOT recipients is not recommended. Further, the need for therapy for mild or asymptomatic cases is not clear. Prospective studies have shown that AdV viremia may be asymptomatic and may clear spontaneously.<sup>144</sup> We reserve treatment (with cidofovir) for symptomatic patients or those with dissemination. AdV infections in organ transplant recipients are discussed elsewhere in this issue by Dr. Weigt et al and will not be further discussed here.

### Human Immunodeficiency Virus Infection

The risk for AdV infection in patients with acquired immunodeficiency syndrome (AIDS) is 28% at 1 year (17% if the CD4 count is  $>200/\text{mm}^3$  vs 38% if the CD4

count is  $<200/\text{mm}^3$ ).<sup>154</sup> The GI tract is involved in  $>90\%$ , but most patients are asymptomatic or have mild symptoms (eg, diarrhea).<sup>154</sup> UTIs may occur in up to 20% of AIDS patients, but bladder inflammation or bleeding is rare.<sup>79</sup> Serotype D is associated with GI infection, whereas UTIs are usually caused by serotype B or D.<sup>154</sup> AdV (particularly serotypes 1, 2, 3) may cause fatal cases in HIV-infected patients.<sup>79</sup> Since the advent of highly active antiretroviral therapy (HAART), AdV disease is uncommon in HIV/AIDS patients until immune system deterioration occurs.<sup>79</sup>

### Congenital Immunodeficiency Syndromes

AdV may complicate congenital immunodeficiency disorders such as severe combined immunodeficiency (SCID) syndrome, agammaglobulinemia, common variable immunodeficiency, immunoglobulin A deficiency, and others.<sup>53,79,155</sup> Patients with SCID are most susceptible. In these patients, AdV tends to cause severe and recurrent pulmonary infections, disseminated disease, and even death.<sup>79</sup> Incidence data for AdV in patients with congenital immunodeficiencies are limited.<sup>79</sup> A review of 201 patients with Bruton X-linked agammaglobulinemia cited only one death due to AdV infection.<sup>155</sup>

### IMPORTANCE OF SEROTYPES

Globally, serotypes 1 through 5, 7, 21, and 41 are most commonly associated with human disease (Table 1). Different serotypes display different tissue tropisms and correlate with clinical manifestations of infection.<sup>1,22,27,29</sup> Among children, the most common AdV serotypes associated with RTIs are types 1 through 7 and 11.<sup>27,156</sup> In adults (particularly military recruits), serotypes implicated in FRIs include subspecies B1 (AdV-3, 7, 11, 16, and 21), species C (AdV-1, 2, 5, and 6), and species E (AdV-4).<sup>8,20,30,63</sup> Historically, most infections among U.S. military recruits were due to AdV strains 4 and 7.<sup>12,13,65</sup> Recently, AdV-14 (a subspecies B2 serotype) was implicated as a cause of severe FRI in

**Table 1 Adenovirus Serotype According to Geographic Region**

Country	1 (%)	2 (%)	3 (%)	4 (%)	7 (%)	21 (%)	41 (%)
United States (2004–07) (civilians) <sup>126</sup>	17.7	24.3	34.6	4.8	3.0	2.0	1.7
United States (2004–07) (military) <sup>126</sup>	NA	NA	2.6	92.8	NA	2.4	NA
Toronto (2007–08) <sup>4</sup>	18	26	46	4.8	NA	5.5	NA
Korea (1991–2007) <sup>27</sup>	9.2	11.2	37	3.9	23.3	NA	NA
Taiwan (1981–1989) <sup>9</sup>	NA	6	68	0	3	NA	NA
Taiwan (2000) <sup>9</sup>	NA	6	36	28	21	NA	NA
Taiwan (2001) <sup>9</sup>	NA	15	2	52	1	NA	NA
Taiwan (2004–05) <sup>2</sup>	4.1	6.4	87.2	0.6	NA	NA	NA
United Kingdom (1982–1996) <sup>180</sup>	12.1	18.6	14.9	NA	NA	NA	10.9

NA, not available.

both military and civilian populations in the United States.<sup>14,20,29,157,158</sup> Other B2 subspecies rarely cause FRIs but AdV-11 (a B2 subspecies) was implicated in outbreaks of FRIs in China,<sup>70</sup> Singapore,<sup>33</sup> the Middle East,<sup>159</sup> the United States,<sup>17</sup> and Latin America.<sup>160</sup> AdV-11 may also cause UTIs or HC in children or transplant recipients.<sup>3,29,79</sup> Other serotypes associated with HC include AdV-33, 34, and 35.<sup>3,29</sup> AdV-35 was also implicated in an epidemic of pneumonia in a chronic psychiatric facility.<sup>67</sup> Species D (AdV-8, 19, and 37) usually cause conjunctivitis,<sup>27,82,161</sup> but more common serotypes (eg, AdV-3, 4, 7, and 11) can also cause conjunctivitis.<sup>9,57</sup> Gastroenteritis is associated with enteric AdV strains 40 and 41 (species F)<sup>3,162</sup>; AdV-12, 18, and 31 (species A)<sup>3</sup>; and AdV-52 (species G).<sup>28</sup> Serotypes AdV-5, 31, 34, 35, and 39 have been implicated in outbreaks in immunocompromised patients,<sup>32,40,135,156,163</sup> particularly HSCT<sup>1,32,97,164,165</sup> or SOT<sup>108,166</sup> recipients. In some patients, multiple serotypes or species were isolated concomitantly.<sup>167</sup>

### Molecular Characterization of AdV

Different genome types *within serotypes* have been identified by restriction enzyme analysis,<sup>63</sup> multiplex PCR techniques targeting fiber genes<sup>168</sup> or hypervariable regions of the hexon genes, and sequencing of the fiber genes<sup>25,169</sup> and hexon genes.<sup>25,27,170</sup> The widely used genotyping system was proposed and modified by Li et al.<sup>10,171</sup> The prototype AdV strain is designated “p”; other genome types within the serotype are designated “a” through “k.” Genome types may be further distinguished by restriction pattern with selected enzymes (eg, AdV-7p, AdV-7p1, etc.).<sup>10,63</sup> Using this system, at least 27 genome types of AdV-7 were identified.<sup>69</sup> This system has been used to correlate genomic types with geographic distribution and pathogenic potential.<sup>63</sup> New serotype(s) may emerge as the dominant pathogen(s), and may exhibit heightened virulence or transmissibility from earlier strains.

The fiber gene mediates attachment of AdV to the host cell.<sup>172,173</sup> Different fiber types display different tissue tropisms. For example, AdV-11p causes mostly UTIs, whereas AdV-11p1, AdV-11a, and AdV-14p exhibit a tropism for the respiratory tract.<sup>30</sup> Most AdVs utilize the coxsackie-AdV receptor (CAR), except for species B viruses that use CD46, a complement protein, as a receptor.<sup>173</sup> A secondary interaction with specific integrins is required for viral entry.

### Global Epidemiology

The predominant serotypes differ among different countries or regions, and they change over time.<sup>2,10,27,63,75,174–177</sup> Transmission of novel strains

between countries or across continents and replacement of dominant serotypes by new strains may occur.<sup>29,178</sup>

Serotypes 1 through 7 account for >80% of AdV infections in infants and children.<sup>27,179</sup> In the United States from 2004 to 2006, the most common serotypes among respiratory isolates from civilians (children or adults) were AdV-3 (34.6%), AdV-2 (24.3%), AdV-1 (17.7%), AdV-5 (5.3%), AdV-4 (4.8%), AdV-7 (3.0%), AdV-21 (2.0%), and AdV-41 (1.7%)<sup>126</sup> (Table 1). In Toronto, Ontario, Canada, the most common serotypes (2007–08) (respiratory isolates) were AdV-3 (46%), AdV-2 (26%), AdV-1 (18%), and AdV-21 (5.5%)<sup>4</sup> (Table 1). In a survey in the United Kingdom (1982 to 1996), most common serotypes implicated in AdV infections (all sites) were AdV-2 (18.6%), AdV-3 (14.9%), AdV-1 (12.1%), and AdV-41 (10.9%).<sup>180</sup>

In Latin America, AdV-7 has been the predominant strain associated with RTI in many countries.<sup>8,160</sup> In Argentina and Uruguay, AdV-7 accounted for 62.4% of AdV RTI in children from 1991 to 1994, followed by species C serotypes (AdV-1, 2, and 5).<sup>160</sup> Notably, AdV-4 was isolated in only one patient (0.6%).<sup>160</sup> In Brazil, AdV-7 was the predominant serotype for decades, but an outbreak of AdV-3 was noted in 2000.<sup>8</sup>

In Asia, AdV-3 and AdV-7 have been the predominant serotypes associated with RTI in children.<sup>9,10,181</sup> A survey of isolates from children with RTIs in South Korea from 1991 to 2007 implicated the following serotypes: AdV-3 (37.0%), AdV-7 (23.3%), AdV-2 (11.2%), AdV-1 (9.2%), AdV-5 (5.9%), AdV-4 (3.9%), AdV-11 (3.4%), and AdV-6 (1.8%)<sup>27</sup> (Table 1). In southern Taiwan, AdV-3 accounted for 68% of AdV RTIs from 1981 to 1989, 44% from 1990 to 1998, 36% in 2000, and 46% in 2002.<sup>2,9,11</sup> In Beijing, China, AdV-3 was the predominant cause of AdV RTIs from 1962 to 1985.<sup>10</sup>

Striking differences in distribution of serotypes have been noted in civilian and military populations. In the United States from 2004 to 2006, AdV-3 was implicated in 34.6% of respiratory AdV infections among civilians, AdV-4 in 4.8%, and AdV-21 in 2.0%<sup>126</sup> (Table 1). By contrast, during that same time frame, AdV-4 accounted for 92.8% of AdV RTIs among military recruits, AdV-3 for 2.6%, and AdV-21 for 2.4%.<sup>126</sup> A previous survey in the United States from 1999 to 2002 implicated AdV-4 in >95% of AdV RTIs among military recruits.<sup>182</sup> Interestingly, between 2002 and 2006, diverse B serotypes (AdV-3, 7, 21, and 14) emerged among U.S. military recruits.<sup>182</sup> After 2006–07, AdV-14 emerged as the predominant serotype in U.S. military recruits.<sup>29</sup>

Changes in serotypes and genome types among geographic regions underscore the potential for new strains to evolve and replace existing strains. Globally, AdV-7c and 7b were the predominant AdV-7 genotypes in North America, Europe, and Australia from the 1960s

to the 1980s.<sup>9,176</sup> In Beijing, China, AdV-7d predominated from 1980 to 1990<sup>10</sup> and was responsible for outbreaks in Japan in 1995<sup>183</sup> and Korea in the 1990s.<sup>181</sup> In Latin America, AdV-7b had been the predominant AdV-7 subtype,<sup>8</sup> but in the mid-1980s a new strain (AdV-7h) emerged in Argentina,<sup>178,184</sup> Brazil,<sup>8</sup> and Chile<sup>178</sup> and largely replaced AdV-7b.<sup>8</sup> In Taiwan, all isolates of AdV-7 during the 1999 to 2001 outbreaks were AdV-7b.<sup>9</sup> In the United States, the AdV-7 prototype strain (Ad7p) accounted for two thirds of AdV-7 isolates from 1966 to 2000.<sup>63</sup> AdV-7d2 first appeared in the United States in 1993 and since 1996 was implicated in several civilian and military outbreaks in the United States and Canada.<sup>63</sup> AdV-7h was first identified in the United States in 1998.<sup>63</sup> The appearance of AdV-7d2 and AdV-7h in North America represents recent introduction of these viruses and may herald a shift in predominant genome types circulating in the United States.

Among AdV-3 strains, AdV-3a, 3b, and p have predominated in the United States and globally since the 1960s.<sup>54,185,186</sup> In the 1980s, three major clusters of AdV-3, comprising 17 genomic types, were noted among six continents.<sup>185</sup> Cluster 1 occurred in Africa, Europe, South America, and North America. Genomic cluster 2 was identified in Africa; genomic cluster 3 was identified in Africa, Asia, Australia, Europe (a few), and North America. In Europe, AdV-3p1 and AdV-3b predominated from 1961 to 1980, whereas AdV-3p and AdV-3p1 predominated in the United States.<sup>185</sup> In Korea, epidemics of AdV-3 in children from 1991 to 1999 were due to AdV-3a and included six novel genotypes.<sup>181</sup> In the People's Republic of China, AdV-3a2 genotype was the predominant AdV-3 genome type from 1962 to 1985.<sup>10</sup> Since 1983, AdV-3a4, 3a5, and 3a6 have occurred in parallel with AdV-3a2 in China.<sup>185</sup> In Taiwan, all AdV-3 isolates during an outbreak (2004–05) were AdV-3a2.<sup>2</sup> In 2006–07, an outbreak of AdV-3 infections due to a novel strain (AdV-3a51) was reported in New Haven, Connecticut.<sup>187</sup>

### Epidemiology and Characteristics of Specific Serotype

Given the large number of AdV serotypes ( $n = 53$ ), a discussion of each serotype is beyond the scope of this review. However, the following sections discuss a few of the common serotypes (eg, AdV-1, 2, 3, 4, 7, 21), additional serotypes associated with specific clinical syndromes (eg, AdV-8, 37, 40, 41), and the recent emergence of AdV-14 in the United States.

#### ADENOVIRUS SEROTYPES 1 AND 2

Serotypes AdV-1 and 2 (both species C) are common causes of epidemic FRIs worldwide but appear to be less virulent than AdV-7<sup>9,160,178</sup> or AdV-3.<sup>77,160</sup> The prev-

alence of AdV-1 and AdV-2 varies among different geographic regions and populations. In the United States (2004–06), AdV-1 and AdV-2 accounted for 17.6% and 24.3% of AdV clinical respiratory isolates among civilians (children or adults), respectively, but only 0.4% and 0.4% among military recruits.<sup>126</sup> The prevalence of these serotypes at other sites is variable: Toronto, Ontario, Canada (2007–08), AdV-1 (18%), AdV-2 (26%)<sup>4</sup>; United Kingdom (1982 to 1996), AdV-1 (12.1%), AdV-2 (18.6%)<sup>180</sup>; Buenos Aires (1984 to 1988), AdV-1 (10%), AdV-2 (20%)<sup>178</sup>; Seoul, South Korea (1990 to 1998), AdV-1 (9.2%), AdV-2 (11.2%)<sup>77</sup>; Taiwan (2004–05), AdV-1 (4.1%), AdV-2 (6.4%).

#### ADENOVIRUS SEROTYPE 3

Globally, AdV-3 is among the most common serotypes implicated in AdV infections in children and adults.<sup>2,73,126,185</sup> AdV accounted for 13% of AdV respiratory isolates reported to the World Health Organization from 1967 to 1976<sup>73</sup> and continues to be a cause of endemic and epidemic infections<sup>2,4,15,126,180</sup> (Table 1). In the United States and southern Ontario from 2004 to 2006, AdV-3 accounted for 34.6% of AdV RTI in civilians and 2.6% among military trainees.<sup>126</sup> The prevalence of AdV-3 at other sites is variable: Toronto, Ontario, Canada (2007–08), 46%<sup>4</sup>; United Kingdom (1982 to 1996), 14.9%<sup>180</sup>; Seoul, South Korea (1990 to 1998), 15%<sup>77</sup>; Seoul, South Korea (1991 to 2007), 37.0%.<sup>27</sup> AdV-3 (along with AdV-7) was the most common cause of AdV RTIs in South Korea,<sup>77,181</sup> Taiwan,<sup>9</sup> and China.<sup>10</sup> In Taiwan, during an outbreak of respiratory AdV infections in children from November 2004 to February 2005, AdV-3 was implicated in 87.5% of cases.<sup>2</sup> However, changes in serotype distribution may occur. In Taiwan, AdV-3 was the predominant serotype from 1981 to 1989 (68%) and 1990–98 (44%) but decreased to 2% of respiratory isolates in 2001 (largely replaced by AdV-4 and AdV-7).<sup>9</sup>

Importantly, AdV-3 may cause fatal pneumonias in immunocompetent children<sup>181,188</sup> and adults.<sup>54</sup> AdV-3 and a recombinant strain of AdV-3/7 were responsible for an outbreak of FRIs (including two fatalities) in children in Portugal in 2004.<sup>188</sup>

#### ADENOVIRUS SEROTYPE 4

AdV-4 is a cause of sporadic infections in civilians<sup>4</sup> and has been implicated in epidemics of FRI or pneumonia in civilian<sup>9,189</sup> and military<sup>14,16,64,133</sup> populations. In civilian populations, AdV-4 was implicated in 4.8% of AdV RTI in the United States (2004 to 2006)<sup>126</sup>; 1% in Toronto, Ontario, Canada (2007–08)<sup>4</sup>; 3.9% (pediatric isolates) in South Korea (1991 to 1997).<sup>27</sup> In Taiwan, AdV-4 accounted for 29% of pediatric respiratory isolates from 1981 to 2001, and became the predominant serotype (52%) in 2001.<sup>9</sup> Until recently, AdV-4 was the most common serotype associated with FRI in U.S.

military recruits.<sup>14,69,133,190</sup> The strategy of vaccinating all military recruits against AdV-4 and AdV-7 beginning in 1971<sup>131,191</sup> eliminated both serotypes as causes of epidemic of FRI in the military for more than 2 decades.<sup>69</sup> After the vaccine was depleted, an outbreak of AdV-4 occurred at an army basic training site in 1997.<sup>64</sup> Over the next several years, AdV-4 spread to multiple secondary sites.<sup>16</sup> From 1999 to 2004, AdV-4 accounted for >95% of AdV FRIs among U.S. military recruits.<sup>16</sup> By 2006–07 the novel strain AdV-14 largely replaced AdV-4 as a cause of AdV FRI among U.S. military recruits.<sup>29</sup>

### ADENOVIRUS SEROTYPE 7

Globally, AdV-7 was the third most common serotype reported to the World Health Organization (WHO) from 1967 through 1976, following AdV-1 and AdV-2,<sup>73</sup> and remains one of the leading serotypes worldwide.<sup>27,63,192</sup> AdV-7 infections manifest as FRI, pharyngoconjunctival fever, bronchitis, necrotizing bronchiolitis, or pneumonia.<sup>63,160,183</sup> Importantly, AdV-7 appears to be more virulent than other serotypes.<sup>9,77,160,174,181,193</sup> Fatal pneumonias may occur in immunocompetent children<sup>5,160,184,194,195</sup> and adults.<sup>19</sup>

Epidemic AdV-7 infections have been reported in the United States,<sup>5,195,196</sup> Canada,<sup>194</sup> Latin America,<sup>160,197</sup> Australia,<sup>198</sup> Israel,<sup>175</sup> South Korea,<sup>65,77</sup> Japan,<sup>174,183</sup> China,<sup>10</sup> and globally.<sup>126,175</sup> Outbreaks typically occur in closed settings, such as military barracks,<sup>15</sup> chronic care facilities,<sup>69</sup> hospitals,<sup>5</sup> and neonatal<sup>66</sup> and pediatric<sup>5,199,200</sup> units. In the late 1960s, AdV-7 and AdV-4 accounted for most cases of FRI among U.S. military recruits.<sup>69,190</sup> Following routine vaccination of U.S. military recruits beginning in 1971,<sup>131,191</sup> no epidemics of FRI were attributed to AdV-7 or AdV-4 from 1984 through 1994.<sup>69</sup> However, in 1997, after the vaccine supply was depleted, an epidemic (> 500 cases) of AdV FRI in a U.S. Navy training site was attributed to serotypes AdV-7 (70%) and AdV-3 (24%).<sup>15</sup> Since 2007, AdV-7 has largely disappeared as a cause of FRI in U.S. military settings (replaced by AdV-14).<sup>29</sup>

The prevalence of AdV-7 varies according to geographic regions and over time and depends on strain type, herd immunity in the region, and epidemiological settings.<sup>5,69,126,195</sup> In the United States from 2004 to 2006, AdV-7 accounted for only 5/581 (0.9%) of clinical AdV respiratory isolates in military facilities and 48/1653 (2.9%) isolates in civilian settings.<sup>126</sup> In Toronto, Ontario, Canada, AdV-7 was not detected among 96 AdV respiratory isolates from 2007 to 2008.<sup>4</sup> By contrast, AdV-7 has been a prominent cause of FRI in Latin America<sup>160,197</sup> and Asia.<sup>27,77,192</sup> AdV-7 was the leading cause of death due to AdV pneumonia in Latin America in the 1980s and 1990s.<sup>160,197</sup> In a study of 165 AdV RTIs in children in Argentina and Uruguay, AdV-7

accounted for 62.2% of isolates and was responsible for 17 of 18 fatalities.<sup>160</sup> The prevalence of AdV-7 as a cause of AdV FRI in Asia is variable, ranging from <1%<sup>174</sup> to >60%.<sup>65</sup> In Seoul, South Korea, from 1990 to 1998, AdV-7 accounted for 41% of RTIs, followed by AdV-3 (15%) and AdV-2 (15%).<sup>77</sup> From 1991 to 2007 in Seoul, AdV-7 accounted for 23.3% of pediatric respiratory AdV isolates, second only to AdV-3 (37.0%)<sup>27</sup> (Table 1). Outbreaks of AdV-7 infections in Korea from 1995 to 2000 were due to diverse genome types; one genome type (AdV7d) may have been introduced from Japan.<sup>192</sup> In a survey of 200 military recruits in South Korea in 2006, 122 recruits (61%) developed AdV FRIs.<sup>65</sup> All 122 isolates were caused by AdV-7. By contrast, in Taiwan, AdV-7 was implicated in only 2% of AdV RTIs in children in 2001, but 19% in 2002.<sup>11</sup> In Taiwan, AdV-7 emerged as the predominant serotype (45%) in 1999–2000 but fell drastically to 1% in 2001 (replaced by AdV-4).<sup>9</sup> In Beijing, China, AdV-7 and AdV-3 were the most common serotypes causing pneumonia from 1958 to 1990.<sup>10</sup> In Japan, AdV-7 constituted <1% of AdV infections from 1981 to 1992 (one to four cases per year), but increased to >100 cases/year from 1995 to 1997.<sup>174</sup>

At least 27 genome types of Ad-7 have been identified by enzyme restriction fragment analysis<sup>69</sup>; shifts or replacement of predominant genome types may occur.<sup>63,126,175,176</sup> Globally, AdV-7c and 7b were the predominant subtypes in the 1960s and 1970s.<sup>176</sup> A shift from AdV-7c to AdV-7b was noted in Europe in 1969, and in 1975 in Australia.<sup>176</sup> During the 1970s, AdV-7b was the predominant subtype in the United States, Europe, and Australia.<sup>176</sup> During that decade, AdV-7c was detected in South Africa, AdV-7d in China, AdV-7e in Brazil, and AdV-7f in Australia.<sup>176</sup> A new subtype (AdV-7d)<sup>175</sup> was associated with sporadic<sup>175</sup> and epidemic FRIs in children<sup>69</sup> and military recruits.<sup>15</sup> Sporadic and epidemic spread of AdV-7a was noted in hospitals<sup>5,66</sup> and other closed community settings.<sup>71</sup> In Buenos Aires from 1984 to 1988, 29 cases of FRI due to a new strain (AdV-7h) were reported; 84% were children <1 year old; more than half ( $n = 16$ ) required intensive care unit (ICU) care: 10 patients with multifocal pneumonia or necrotizing bronchiolitis died.<sup>184</sup> In a review of 73 pediatric cases of AdV FRI in Buenos Aires between 1984 and 1988, AdV-7h was implicated in 25 and was responsible in all six deaths.<sup>178</sup> A similar strain had been circulating in Chile from 1984 to 1987.<sup>178</sup> Pediatric respiratory AdV-7 isolates from Uruguay, Chile, and Argentina from 1984 to 1990 included AdV-7b, 7c, and 7h.<sup>197</sup> AdV-7c predominated in 1984, but AdV-7h emerged as the predominant strain in 1986. AdV-7b cocirculated during this period but was of lower virulence.<sup>197</sup> AdV-7h accounted for 61.2% of AdV RTIs in children in Argentina and Uruguay from 1991 to 1994 and was responsible for 17 of 18 fatalities.<sup>160</sup> In São



Paulo, Brazil, in 1995, AdV-7h replaced AdV-7b, which had been the predominant AdV-7 subtype for more than a decade.<sup>8</sup> In the United States and eastern Ontario from 1966 to 2000, AdV-7b accounted for 65% of clinical respiratory isolates of AdV-7, followed by AdV-7c (28%), and AdV-7h (2%).<sup>63</sup> AdV-7d2 was first detected in the United States in 1993; AdV-7h was first detected in the U.S. Southwest in 1998.<sup>63</sup> Since 1996, AdV-7d was responsible for several civilian and military epidemics in the United States.<sup>63</sup> In Beijing, China, AdV-7d was the predominant AdV-7 subtype responsible for AdV pneumonia from 1980 to 1990.<sup>10</sup> In Taiwan, AdV-7a was detected in 1983 but all clinical isolates from 1999 to 2001 were AdV-7b.<sup>9</sup> In Israel, four genotypes (AdV-7a1, 7b, 7d2, and 7k) were detected among clinical isolates from 1968 to 1995.<sup>175</sup> These various studies emphasize that new serotypes may emerge as the dominant pathogen and may exhibit heightened virulence or transmissibility from earlier strains.

#### ADENOVIRUS SEROTYPE 8

AdV-8 accounts for <1% of AdV infections<sup>4,27,77,126</sup> but is a well-recognized cause of EKC.<sup>77,82,87,93</sup> In four studies in Asia and the Middle East, AdV-8 accounted for 64 to 79% of EKC due to AdV.<sup>82,83,89,95</sup> Conjunctival hemorrhage, corneal involvement, and preauricular lymphadenopathy were noted in most cases.<sup>82</sup>

#### ADENOVIRUS SEROTYPE 11

AdV-11 is relatively uncommon, but may cause hemorrhagic conjunctivitis<sup>34–36,70</sup> and FRI (including pneumonia) in immunocompetent patients and hemorrhagic cystitis in immunocompromised patients.<sup>17,70</sup> In the United States from 2004 to 2006, AdV-11 accounted for <1% of AdV RTI in military recruits and civilians<sup>126</sup>; in Toronto, Ontario, Canada, AdV-11 was not detected among 96 clinical respiratory AdV isolates (Table 1). By contrast, AdV-11 represented 3.4% of 741 pediatric respiratory isolates from South Korea from 1991 to 2007.<sup>27</sup> Outbreaks of AdV-11 FRIs were described in Asia,<sup>33,70</sup> South America,<sup>160</sup> the United States,<sup>17,182</sup> the Middle East,<sup>159</sup> and globally. AdV-11 may cause UTI, including hemorrhagic cystitis, in organ transplant recipients (particularly children).<sup>1,56,105,201</sup> AdV may remain dormant in the renal parenchyma until it is reactivated by an impaired immune system.<sup>56</sup>

#### EMERGENCE OF ADENOVIRUS SEROTYPE 14 IN THE UNITED STATES

AdV-14 was first isolated in the Netherlands in 1955 during an outbreak of acute respiratory disease (ARD) among military recruits,<sup>29</sup> AdV-14 was subsequently isolated during similar outbreaks of ARD in Great Britain in 1955,<sup>202</sup> Uzbekistan in 1962,<sup>29</sup> and Czechoslovakia in 1963.<sup>29</sup> Interestingly, apart from sporadic isolations in the Netherlands in the early 1970s, no cases

of AdV-14 infections were reported globally between the 1960s and 2004.<sup>11,29</sup> A retrospective study of children hospitalized in Taiwan during 2001–02 with ARD implicated AdV-14 in 2 to 11% of isolates.<sup>11</sup> However, AdV-14 had never been identified in North America before its emergence in 2006.<sup>30</sup> Beginning in March 2006, outbreaks of FRI due to AdV-14 (several hundred cases) were noted in several U.S. military bases.<sup>61,75,182,203</sup> Subsequent cases among health care workers suggested nosocomial infection.<sup>61</sup> Surveillance cultures from patients with FRIs from 21 military training sites in 2007 detected AdV-14 at multiple sites in California, Florida, Mississippi, Texas, and South Korea.<sup>75</sup> By 2007, several outbreaks in civilian populations were documented in Washington,<sup>157</sup> Oregon,<sup>204</sup> Alaska,<sup>158</sup> Wisconsin,<sup>29</sup> Pennsylvania,<sup>29</sup> and at least 15 states.<sup>20,29</sup> The severity of FRIs was variable, but fatal pneumonias were described.<sup>20,29,61,157,204</sup> Reconstruction of the history of circulation of AdV-14 in the United States traced the earliest detected case of infection to California in December 2003.<sup>29</sup> In Oregon, AdV-14 emerged in October 2005 and became the predominant circulating serotype by 2007.<sup>204</sup> By 2007, AdV-14 had replaced AdV-4 as the dominant serotype on U.S. military bases.<sup>30,182</sup> Analysis of 99 isolates recovered from patients (military and civilian) with AdV FRI between December 2003 and June 2009 from different geographic locations confirmed that all isolates were identical.<sup>29</sup> These isolates represented a new genomic type designated AdV-14p1 (formerly known as 14a).<sup>29</sup> The complete genetic sequence of AdV-14p1 indicates a close relationship to AdV-11a, suggesting recombination between AdV-14 and AdV-11 strains.<sup>30</sup> Enhanced surveillance and identification of early cases, infection control measures, cohorting, and restricting travel curbed epidemics at several sites,<sup>75</sup> but endemic and epidemic cases have continued in some locales.<sup>29</sup> As a recently emerged virus, AdV-14p1 has an increased potential for high attack rates and rates of transmission, owing to the lack of herd immunity.<sup>30</sup>

#### ADENOVIRUS SEROTYPE 21

AdV-21 was associated with epidemics of FRIs in military recruits in the Netherlands in the 1960s,<sup>205</sup> but only sporadic cases were noted over the next 2 decades.<sup>206</sup> In 1984 and 1985, outbreaks of AdV-21 infections in children in the Netherlands and Germany reflected the emergence of closely related variants of the original AdV-21 in the 1960s.<sup>206</sup> AdV-21 has been associated with pharyngitis and conjunctivitis,<sup>207</sup> FRI,<sup>163</sup> and pulmonary complications (eg, bronchiectasis, bronchiolitis obliterans) in children<sup>208</sup> but is uncommon.<sup>27</sup> In the United States from 2004 to 2006, AdV-21 accounted for 2.0% and 2.4% of AdV RTI in civilians and military recruits, respectively.<sup>126</sup> In Toronto, Ontario, Canada (2007–08), AdV-21 accounted for 5.5% of

clinical respiratory AdV isolates. By contrast, AdV-21 was never isolated in 741 pediatric respiratory isolates from Korea from 1991 to 2007.<sup>27</sup> Interestingly, Adv-21 may be less transmissible than other AdV serotypes. In an isolated station in Antarctica, only 15% of individuals developed clinical infections over a 5-week period, despite contact with infected individuals and low baseline humoral immunity (neutralizing antibody titer >1:3 in only 11%).<sup>209</sup>

#### ADENOVIRUS SEROTYPE 31

AdV-31 may cause gastroenteritis in healthy children and has been associated with severe (sometimes) fatal infections in HSCT recipients.<sup>24,121,210–212</sup> Nosocomial transmission (seven cases) in a pediatric HSCT unit was described<sup>212</sup>

#### ADENOVIRUS SEROTYPE 37

AdV-37 accounts for <1% of AdV infections<sup>4,27,77,126</sup> but may cause epidemic keratoconjunctivitis.<sup>77,82,83,85,87–89</sup>

#### ADENOVIRUS SPECIES F (SEROTYPES 40 AND 41)

Globally, AdV species F (serotypes 40 and 41) are endemic and typically cause gastroenteritis and diarrheal illness in children.<sup>39–50</sup> Fatalities may occur as a result of dehydration in infants.<sup>39,40</sup> In immunocompromised hosts (particularly HSCT recipients), fatal dissemination may occur<sup>58,213</sup> but is rare. Epidemics have been cited in schools<sup>45</sup> and hospitals.<sup>58</sup> Endogenous reactivation (probably originating from AdV persistent in mucosal lymphoid cells)<sup>55</sup> may occur. Nosocomial transmission may occur due to high AdV levels in feces during diarrheal illnesses.<sup>58</sup> Importantly, shedding of these viruses may be prolonged in immunosuppressed patients.<sup>58</sup> In one pediatric HSCT unit, six children developed AdV-41 infection within 2 weeks (principal manifestation gastroenteritis and mild hepatitis).<sup>58</sup> The outbreak was curtailed following strict infection control procedures.

#### Diagnosis of Adenovirus Infection

AdV can be detected in affected sites [eg, nasopharyngeal aspirates, swabs, washings, bronchoalveolar lavage (BAL), urine, stool, blood] by virus-specific direct or indirect immunofluorescent stains, conventional or shell vial cultures, or PCR.<sup>3,27</sup> Viral cultures by conventional techniques are the gold standard but could be insensitive for certain samples (eg, blood) and may take up to 21 days to detect the cytopathic effect.<sup>1,3,27</sup> Biopsy of involved tissues may reveal AdV nuclear inclusions<sup>1</sup>; immunohistochemical stains may identify the AdV hexon antigen.<sup>114</sup> PCR of AdV DNA in plasma, urine, or infected sites may establish the diagnosis<sup>1,142</sup> and is highly sensitive for disseminated disease.<sup>214,215</sup> Quantification of the viral load using real-

time PCR is a useful marker to assess response to therapy.<sup>139,214</sup> Among transplant recipients, serial PCR assays of blood and stool weekly may detect AdV disease prior to the onset of symptoms and facilitate early, preemptive therapy.<sup>22,117,138,144</sup> The role of routine surveillance is controversial, although it has been increasingly used, especially in high-risk patients.<sup>1</sup> Quantitative viral loads may not correlate with clinical presentation or disease severity.<sup>32</sup> The study of the viral kinetics may be more useful to determine prognosis of disease.

Determination of serotype with the neutralization test is laborious and time consuming. Multiplex PCR-based techniques targeting the fiber genes<sup>168</sup> or hypervariable regions of the hexon<sup>170</sup> and/or sequencing of hexon genes allows definitive identification of the serotype/species.<sup>25,27</sup> Serological tests may be useful in epidemiological investigations but are of limited practical value in individual patients.<sup>79</sup>

#### THERAPY

No antiviral drug has been approved to treat AdV.<sup>79</sup> Prospective randomized, controlled trials are lacking. Ganciclovir displays *in vitro* activity against AdV but has no role to treat AdV infections.<sup>1</sup> Ribavirin, a guanoside analogue, has antiviral activity against both DNA and RNA viruses.<sup>216</sup> More importantly, in small clinical studies, ribavirin has not been shown to be efficacious.<sup>137,215</sup> Cidofovir (CDV), a cytosine nucleotide analogue that inhibits DNA polymerase, has the greatest *in vitro* activity against AdV<sup>216–218</sup> and is the preferred therapeutic agent.<sup>1</sup> CDV is available only intravenously.<sup>1</sup> Regimens (dosing, frequency, duration) are variable. The standard dose is 5 mg/kg every 1 to 2 weeks<sup>79,138</sup> or 1 mg/kg twice weekly.<sup>79,122,138</sup> Duration of therapy is variable (weeks to months) and depends upon clinical response and persistence or eradication of AdV.<sup>122,138</sup> Although CDV is generally well tolerated,<sup>117,138</sup> adverse effects include nephrotoxicity, myelosuppression, and uveitis.<sup>1,79</sup> Hydration and probenecid may minimize nephrotoxicity.<sup>1,109,117,219</sup> Careful monitoring of renal function (serum creatinine, proteinuria) is critical.

Numerous nonrandomized studies in HSCT and SOT recipients documented favorable responses to CDV.<sup>21,22,24,117,122,138,141,166,219–221</sup> In a multicenter trial in allogeneic HSCT recipients, CDV eradicated AdV infection in 20/29 patients (69%) with various clinical manifestations.<sup>220</sup> Another study cited improvement with CDV in 10/14 (77%) HSCT recipients with AdV hemorrhagic cystitis.<sup>222</sup> Intravesicular CDV was beneficial in an HSCT recipient with intractable hemorrhagic cystitis.<sup>105</sup> In a cohort of pediatric HSCT recipients, CDV led to clinical improvement in eight of 10 with severe AdV infection and to viral clearance in

nine patients.<sup>141</sup> However, given the lack of controlled trials, indications for and efficacy of CDV remain controversial.<sup>23</sup> Interpretation of these studies is confounded by heterogeneous patient populations, differing extent and sites of disease, and degree of immunosuppression or immune reconstitution.<sup>79</sup>

Immune reconstitution plays a critical role in controlling AdV infection.<sup>79</sup> Increases in lymphocyte counts or CD4 counts were associated with clearance of AdV infection<sup>223,224</sup> and improved survival.<sup>224,225</sup> Further, serotypic-specific neutralizing antibodies correlate with clearance of AdV.<sup>79,224</sup> Patients whose viremia cleared exhibited an increased humoral response, with an eight- to 16-fold increase in serotype-specific antibodies.<sup>224</sup> In light of these observations, reduction of immunosuppression,<sup>114,117</sup> immune reconstitution of HSCT recipients,<sup>21,79</sup> or donor leukocyte infusions<sup>24</sup> may have adjunctive roles. Intravenous immunoglobulin (IVIg) has been used (together with CDV), but data are insufficient to assess efficacy.<sup>21</sup>

Importantly, not all patients with AdV infections or viremia require treatment.<sup>1,32</sup> High mortality rates in retrospective studies in part reflect that virtually all patients had symptoms attributable to AdV infection. Prospective studies in SOT<sup>144</sup> or HSCT<sup>32</sup> recipients using plasma PCR at regular intervals noted that up to 58% were asymptomatic at the time of viremia, and spontaneous resolution without sequelae was common. In a cohort of SOT recipients with AdV viremia, all 19 recovered spontaneously without sequelae.<sup>144</sup> Similarly, in a study of pediatric HSCT recipients, AdV viremia was detected in 42% and cleared without therapy in 64%.<sup>32</sup> We believe antiviral treatment should be considered for the following indications: disseminated ( $\geq$  two sites) disease, severe pneumonia, high viral loads in blood, virulence or tropism of the viral strain, persistent severe lymphopenia, or immune deficits. Further, preemptive therapy may have a role in viremic but asymptomatic organ transplant recipients at high risk for dissemination. In one study, CDV was administered to 18 pediatric HSCT recipients with asymptomatic viremia; viremia resolved in 13 (81%). Prospective, randomized trials are needed to elucidate indications for therapy in both symptomatic and asymptomatic patients with AdV infections.

## VACCINES

Oral vaccines against AdV types 4 and 7 developed for the U.S. military in 1971<sup>16</sup> were depleted by 1999.<sup>16</sup> A new vaccine for AdV-4 and AdV-7 has been developed; phase 3 has been completed and hopefully vaccination of military populations can be accomplished soon.<sup>16,75</sup> Importantly, antibodies to AdV-4 and AdV-7 may cross protect against other serotypes (eg, AdV-3<sup>75,182</sup> and AdV-14).<sup>75,182,226</sup>

## REFERENCES

- Ison MG. Adenovirus infections in transplant recipients. *Clin Infect Dis* 2006;43(3):331–339
- Chang SY, Lee CN, Lin PH, et al. A community-derived outbreak of adenovirus type 3 in children in Taiwan between 2004 and 2005. *J Med Virol* 2008;80(1):102–112
- Kim Y-J, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. *Semin Respir Crit Care Med* 2007;28(2):222–242
- Yeung R, Eshaghi A, Lombos E, et al. Characterization of culture-positive adenovirus serotypes from respiratory specimens in Toronto, Ontario, Canada: September 2007–June 2008. *Virol J* 2009;6:11
- Mitchell LS, Taylor B, Reimels W, Barrett FF, Devincenzo JP. Adenovirus 7a: a community-acquired outbreak in a children's hospital. *Pediatr Infect Dis J* 2000;19(10):996–1000
- Kojoaghlanian T, Flomenberg P, Horwitz MS. The impact of adenovirus infection on the immunocompromised host. *Rev Med Virol* 2003;13(3):155–171
- Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. *Medicine (Baltimore)* 2006;85(5):278–287
- Moura PO, Roberto AF, Hein N, et al. Molecular epidemiology of human adenovirus isolated from children hospitalized with acute respiratory infection in São Paulo, Brazil. *J Med Virol* 2007;79(2):174–181
- Lin KH, Lin YC, Chen HL, et al. A two decade survey of respiratory adenovirus in Taiwan: the reemergence of adenovirus types 7 and 4. *J Med Virol* 2004;73(2):274–279
- Li QG, Zheng QJ, Liu YH, Wadell G. Molecular epidemiology of adenovirus types 3 and 7 isolated from children with pneumonia in Beijing. *J Med Virol* 1996;49(3):170–177
- Chen HL, Chiou SS, Hsiao HP, et al. Respiratory adenoviral infections in children: a study of hospitalized cases in southern Taiwan in 2001–2002. *J Trop Pediatr* 2004;50(5):279–284
- Kolavic-Gray SA, Binn LN, Sanchez JL, et al. Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies. *Clin Infect Dis* 2002;35(7):808–818
- Sanchez JL, Binn LN, Innis BL, et al. Epidemic of adenovirus-induced respiratory illness among US military recruits: epidemiologic and immunologic risk factors in healthy, young adults. *J Med Virol* 2001;65(4):710–718
- Kajon AE, Moseley JM, Metzgar D, et al. Molecular epidemiology of adenovirus type 4 infections in US military recruits in the postvaccination era (1997–2003). *J Infect Dis* 2007;196(1):67–75
- Ryan MA, Gray GC, Smith B, McKeehan JA, Hawksworth AW, Malasig MD. Large epidemic of respiratory illness due to adenovirus types 7 and 3 in healthy young adults. *Clin Infect Dis* 2002;34(5):577–582
- Russell KL, Hawksworth AW, Ryan MA, et al. Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999–2004. *Vaccine* 2006;24(15):2835–2842

17. Centers for Disease Control and Prevention (CDC). Civilian outbreak of adenovirus acute respiratory disease—South Dakota, 1997. *MMWR Morb Mortal Wkly Rep* 1998;47(27):567–570
18. Zarraga AL, Kerns FT, Kitchen LW. Adenovirus pneumonia with severe sequelae in an immunocompetent adult. *Clin Infect Dis* 1992;15(4):712–713
19. Dudding BA, Wagner SC, Zeller JA, Gmelich JT, French GR, Top FH Jr. Fatal pneumonia associated with adenovirus type 7 in three military trainees. *N Engl J Med* 1972;286(24):1289–1292
20. Louie JK, Kajon AE, Holodny M, et al. Severe pneumonia due to adenovirus serotype 14: a new respiratory threat? *Clin Infect Dis* 2008;46(3):421–425
21. Neofytos D, Ojha A, Mookerjee B, et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. *Biol Blood Marrow Transplant* 2007;13(1):74–81
22. Zheng X, Lu X, Erdman DD, et al. Identification of adenoviruses in specimens from high-risk pediatric stem cell transplant recipients and controls. *J Clin Microbiol* 2008;46(1):317–320
23. Symeonidis N, Jakubowski A, Pierre-Louis S, et al. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. *Transpl Infect Dis* 2007;9(2):108–113
24. Bordigoni P, Carret AS, Venard V, Witz F, Le Faou A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. *Clin Infect Dis* 2001;32(9):1290–1297
25. Lu X, Erdman DD. Molecular typing of human adenoviruses by PCR and sequencing of a partial region of the hexon gene. *Arch Virol* 2006;151(8):1587–1602
26. Henquell C, Boeuf B, Mirand A, et al. Fatal adenovirus infection in a neonate and transmission to health-care workers. *J Clin Virol* 2009;45(4):345–348
27. Lee J, Choi EH, Lee HJ. Comprehensive serotyping and epidemiology of human adenovirus isolated from the respiratory tract of Korean children over 17 consecutive years (1991–2007). *J Med Virol* 2010;82(4):624–631
28. Jones MS II, Harrach B, Ganac RD, et al. New adenovirus species found in a patient presenting with gastroenteritis. *J Virol* 2007;81(11):5978–5984
29. Kajon AE, Lu X, Erdman DD, et al. Molecular epidemiology and brief history of emerging adenovirus 14-associated respiratory disease in the United States. *J Infect Dis* 2010;202(1):93–103
30. Hough HS, Gong H, Kajon AE, et al. Genome sequences of human adenovirus 14 isolates from mild respiratory cases and a fatal pneumonia, isolated during 2006–2007 epidemics in North America. *Respir Res* 2010;11:116
31. Ebner K, Rauch M, Preuner S, Lion T. Typing of human adenoviruses in specimens from immunosuppressed patients by PCR-fragment length analysis and real-time quantitative PCR. *J Clin Microbiol* 2006;44(8):2808–2815
32. Walls T, Hawrami K, Ushiro-Lumb I, Shingadia D, Saha V, Shankar AG. Adenovirus infection after pediatric bone marrow transplantation: is treatment always necessary? *Clin Infect Dis* 2005;40(9):1244–1249
33. Kajon AE, Dickson LM, Metzgar D, Hough HS, Lee V, Tan BH. Outbreak of febrile respiratory illness associated with adenovirus 11a infection in a Singapore military training cAMP. *J Clin Microbiol* 2010;48(4):1438–1441
34. Nakayama M, Miyazaki C, Ueda K, et al. Pharyngoconjunctival fever caused by adenovirus type 11. *Pediatr Infect Dis J* 1992;11(1):6–9
35. Yin-Murphy M, Lim KH, Chua PH. Adenovirus type 11 epidemic conjunctivitis in Singapore. *Southeast Asian J Trop Med Public Health* 1974;5(3):333–341
36. Tai FH, Chu S, Chi WH, Wei HY, Hierholzer JC. Epidemic haemorrhagic conjunctivitis associated with adenovirus type 11 in Taiwan. *Southeast Asian J Trop Med Public Health* 1974;5(3):342–349
37. James L, Vernon MO, Jones RC, et al. Outbreak of human adenovirus type 3 infection in a pediatric long-term care facility—Illinois, 2005. *Clin Infect Dis* 2007;45(4):416–420
38. Ishiko H, Aoki K. Spread of epidemic keratoconjunctivitis due to a novel serotype of human adenovirus in Japan. *J Clin Microbiol* 2009;47(8):2678–2679
39. Filho EP, da Costa Faria NR, Fialho AM, et al. Adenoviruses associated with acute gastroenteritis in hospitalized and community children up to 5 years old in Rio de Janeiro and Salvador, Brazil. *J Med Microbiol* 2007;56(Pt 3):313–319
40. Madisch I, Wölfel R, Harste G, Pommer H, Heim A. Molecular identification of adenovirus sequences: a rapid scheme for early typing of human adenoviruses in diagnostic samples of immunocompetent and immunodeficient patients. *J Med Virol* 2006;78(9):1210–1217
41. Hársi CM, Rolim DP, Gomes SA, et al. Adenovirus genome types isolated from stools of children with gastroenteritis in São Paulo, Brazil. *J Med Virol* 1995;45(2):127–134
42. Fukuda S, Kuwayama M, Takao S, Shimazu Y, Miyazaki K. Molecular epidemiology of subgenus F adenoviruses associated with pediatric gastroenteritis during eight years in Hiroshima Prefecture as a limited area. *Arch Virol* 2006;151(12):2511–2517
43. Sdiri-Loulizi K, Gharbi-Khelifi H, de Rougemont A, et al. Molecular epidemiology of human astrovirus and adenovirus serotypes 40/41 strains related to acute diarrhea in Tunisian children. *J Med Virol* 2009;81(11):1895–1902
44. Magwalivha M, Wolfaardt M, Kiulia NM, van Zyl WB, Mwenda JM, Taylor MB. High prevalence of species D human adenoviruses in fecal specimens from urban Kenyan children with diarrhea. *J Med Virol* 2010;82(1):77–84
45. Gonçalves G, Gouveia E, Mesquita JR, et al. Outbreak of acute gastroenteritis caused by adenovirus type 41 in a kindergarten. *Epidemiol Infect* 2010 Dec 15:1–4. [Epub ahead of print]
46. Li L, Shimizu H, Doan LT, et al. Characterizations of adenovirus type 41 isolates from children with acute gastroenteritis in Japan, Vietnam, and Korea. *J Clin Microbiol* 2004;42(9):4032–4039
47. Marie-Cardine A, Gourelain K, Mouterde O, et al. Epidemiology of acute viral gastroenteritis in children hospitalized in Rouen, France. *Clin Infect Dis* 2002;34(9):1170–1178
48. Soares CC, Volotão EM, Albuquerque MC, et al. Prevalence of enteric adenoviruses among children with diarrhea in four Brazilian cities. *J Clin Virol* 2002;23(3):171–177
49. Cunliffe NA, Booth JA, Elliot C, et al. Healthcare-associated viral gastroenteritis among children in a large pediatric hospital, United Kingdom. *Emerg Infect Dis* 2010;16(1):55–62

50. Iturriza Gómara M, Simpson R, Perault AM, et al. Structured surveillance of infantile gastroenteritis in East Anglia, UK: incidence of infection with common viral gastroenteric pathogens. *Epidemiol Infect* 2008;136(1):23–33
51. King JC Jr. Community respiratory viruses in individuals with human immunodeficiency virus infection. *Am J Med* 1997;102(3A):19–24; discussion 25–26
52. Wigger HJ, Blanc WA. Fatal hepatic and bronchial necrosis in adenovirus infection with thymic lymphoplasia. *N Engl J Med* 1966;275(16):870–874
53. Dagan R, Schwartz RH, Insel RA, Menegus MA. Severe diffuse adenovirus 7a pneumonia in a child with combined immunodeficiency: possible therapeutic effect of human immune serum globulin containing specific neutralizing antibody. *Pediatr Infect Dis* 1984;3(3):246–251
54. Barker JH, Luby JP, Sean Dalley A, Bartek WM, Burns DK, Erdman DD. Fatal type 3 adenoviral pneumonia in immunocompetent adult identical twins. *Clin Infect Dis* 2003;37(10):e142–e146
55. Garnett CT, Erdman D, Xu W, Gooding LR. Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. *J Virol* 2002;76(21):10608–10616
56. Bil-Lula I, Ussowicz M, Rybka B, et al. Hematuria due to adenoviral infection in bone marrow transplant recipients. *Transplant Proc* 2010;42(9):3729–3734
57. Wadell G. Molecular epidemiology of human adenoviruses. *Curr Top Microbiol Immunol* 1984;110:191–220
58. Mattner F, Sykora KW, Meissner B, Heim A. An adenovirus type F41 outbreak in a pediatric bone marrow transplant unit: analysis of clinical impact and preventive strategies. *Pediatr Infect Dis J* 2008;27(5):419–424
59. Buffington J, Chapman LE, Stobierski MG, et al. Epidemic keratoconjunctivitis in a chronic care facility: risk factors and measures for control. *J Am Geriatr Soc* 1993;41(11):1177–1181
60. Singh-Naz N, Brown M, Ganeshananthan M. Nosocomial adenovirus infection: molecular epidemiology of an outbreak. *Pediatr Infect Dis J* 1993;12(11):922–925
61. Lessa FC, Gould PL, Pascoe N, et al. Health care transmission of a newly emergent adenovirus serotype in health care personnel at a military hospital in Texas, 2007. *J Infect Dis* 2009;200(11):1759–1765
62. Russell KL, Broderick MP, Franklin SE, et al. Transmission dynamics and prospective environmental sampling of adenovirus in a military recruit setting. *J Infect Dis* 2006;194(7):877–885
63. Erdman DD, Xu W, Gerber SI, et al. Molecular epidemiology of adenovirus type 7 in the United States, 1966–2000. *Emerg Infect Dis* 2002;8(3):269–277
64. McNeill KM, Ridgely Benton F, Monteith SC, Tuchscherer MA, Gaydos JC. Epidemic spread of adenovirus type 4-associated acute respiratory disease between U.S. army installations. *Emerg Infect Dis* 2000;6(4):415–419
65. Jeon K, Kang CI, Yoon CH, et al. High isolation rate of adenovirus serotype 7 from South Korean military recruits with mild acute respiratory disease. *Eur J Clin Microbiol Infect Dis* 2007;26(7):481–483
66. Finn A, Anday E, Talbot GH. An epidemic of adenovirus 7a infection in a neonatal nursery: course, morbidity, and management. *Infect Control Hosp Epidemiol* 1988;9(9):398–404
67. Sanchez MP, Erdman DD, Torok TJ, Freeman CJ, Matyas BT. Outbreak of adenovirus 35 pneumonia among adult residents and staff of a chronic care psychiatric facility. *J Infect Dis* 1997;176(3):760–763
68. Klinger JR, Sanchez MP, Curtin LA, Durkin M, Matyas B. Multiple cases of life-threatening adenovirus pneumonia in a mental health care center. *Am J Respir Crit Care Med* 1998;157(2):645–649
69. Gerber SI, Erdman DD, Pur SL, et al. Outbreak of adenovirus genome type 7d2 infection in a pediatric chronic-care facility and tertiary-care hospital. *Clin Infect Dis* 2001;32(5):694–700
70. Zhu Z, Zhang Y, Xu S, et al. Outbreak of acute respiratory disease in China caused by B2 species of adenovirus type 11. *J Clin Microbiol* 2009;47(3):697–703
71. Harris DJ, Wulff H, Ray CG, Poland JD, Chin TD, Wenner HA. Viruses and disease. 3. An outbreak of adenovirus type 7A in a children's home. *Am J Epidemiol* 1971;93(5):399–402
72. Chany C, Lepine P, Lelong M, Le TV, Satge P, Virat J. Severe and fatal pneumonia in infants and young children associated with adenovirus infections. *Am J Hyg* 1958;67(3):367–378
73. Schmitz H, Wigand R, Heinrich W. Worldwide epidemiology of human adenovirus infections. *Am J Epidemiol* 1983;117(4):455–466
74. Rubin BA. Clinical picture and epidemiology of adenovirus infections (a review). *Acta Microbiol Hung* 1993;40(4):303–323
75. Trei JS, Johns NM, Garner JL, et al. Spread of adenovirus to geographically dispersed military installations, May–October 2007. *Emerg Infect Dis* 2010;16(5):769–775
76. Sauerbrei A, Sehr K, Brandstädt A, Heim A, Reimer K, Wutzler P. Sensitivity of human adenoviruses to different groups of chemical biocides. *J Hosp Infect* 2004;57(1):59–66
77. Hong JY, Lee HJ, Piedra PA, et al. Lower respiratory tract infections due to adenovirus in hospitalized Korean children: epidemiology, clinical features, and prognosis. *Clin Infect Dis* 2001;32(10):1423–1429
78. Hakim FA, Tleyjeh IM. Severe adenovirus pneumonia in immunocompetent adults: a case report and review of the literature. *Eur J Clin Microbiol Infect Dis* 2008;27(2):153–158
79. Echavarría M. Adenoviruses in immunocompromised hosts. *Clin Microbiol Rev* 2008;21(4):704–715
80. Sly PD, Soto-Quiros ME, Landau LI, Hudson I, Newton-John H. Factors predisposing to abnormal pulmonary function after adenovirus type 7 pneumonia. *Arch Dis Child* 1984;59(10):935–939
81. Cherry J. Adenoviruses. In: Feigin RD, Cherry JD, Demmler GJ, Kaplan SL, eds. *Textbook of Pediatric Infectious Diseases*. 5th ed. Philadelphia, PA: Saunders; 2003:1843–1856
82. Tabbara KF, Omar N, Hammouda E, et al. Molecular epidemiology of adenoviral keratoconjunctivitis in Saudi Arabia. *Mol Vis* 2010;16:2132–2136
83. Aoki K, Tagawa Y. A twenty-one year surveillance of adenoviral conjunctivitis in Sapporo, Japan. *Int Ophthalmol Clin* 2002;42(1):49–54
84. Percivalle E, Sarasini A, Torsellini M, et al. A comparison of methods for detecting adenovirus type 8 keratoconjunctivitis during a nosocomial outbreak in a neonatal intensive care unit. *J Clin Virol* 2003;28(3):257–264

85. Hamada N, Gotoh K, Hara K, et al. Nosocomial outbreak of epidemic keratoconjunctivitis accompanying environmental contamination with adenoviruses. *J Hosp Infect* 2008;68(3):262–268
86. Ishiko H, Shimada Y, Konno T, et al. Novel human adenovirus causing nosocomial epidemic keratoconjunctivitis. *J Clin Microbiol* 2008;46(6):2002–2008
87. Chang CH, Lin KH, Sheu MM, Huang WL, Wang HZ, Chen CW. The change of etiological agents and clinical signs of epidemic viral conjunctivitis over an 18-year period in southern Taiwan. *Graefes Arch Clin Exp Ophthalmol* 2003;41(7):554–560
88. Matsui K, Saha S, Saitoh M, et al. Isolation and identification of adenovirus from conjunctival scrapings over a two-year period (between 2001 and 2003) in Yokohama, Japan. *J Med Virol* 2007;79(2):200–205
89. Jin XH, Ishiko H, Nguyen TH, et al. Molecular epidemiology of adenoviral conjunctivitis in Hanoi, Vietnam. *Am J Ophthalmol* 2006;142(6):1064–1066
90. Ariga T, Shimada Y, Shiratori K, et al. Five new genome types of adenovirus type 37 caused epidemic keratoconjunctivitis in Sapporo, Japan, for more than 10 years. *J Clin Microbiol* 2005;43(2):726–732
91. Itakura S, Aoki K, Sawada H, Shinagawa M. Analysis with restriction endonucleases recognizing 4- or 5-base-pair sequences of human adenovirus type 3 isolated from ocular diseases in Sapporo, Japan. *J Clin Microbiol* 1990; 28(10): 2365–2369
92. Ariga T, Shimada Y, Ohgami K, et al. New genome type of adenovirus serotype 4 caused nosocomial infections associated with epidemic conjunctivitis in Japan. *J Clin Microbiol* 2004;42(8):3644–3648
93. Sendra-Gutiérrez JM, Martín-Rios D, Casas I, Sáez P, Tovar A, Moreno C. An outbreak of adenovirus type 8 keratoconjunctivitis in a nursing home in Madrid. *Euro Surveill* 2004;9(3):27–30
94. Montessori V, Scharf S, Holland S, Werker DH, Roberts FJ, Bryce E. Epidemic keratoconjunctivitis outbreak at a tertiary referral eye care clinic. *Am J Infect Control* 1998;26(4): 399–405
95. Saitoh-Inagawa W, Aoki K, Uchio E, Itoh N, Ohno S. Ten years' surveillance of viral conjunctivitis in Sapporo, Japan. *Graefes Arch Clin Exp Ophthalmol* 1999;237(1): 35–38
96. Kapelushnik J, Or R, Delukina M, Nagler A, Livni N, Engelhard D. Intravenous ribavirin therapy for adenovirus gastroenteritis after bone marrow transplantation. *J Pediatr Gastroenterol Nutr* 1995;21(1):110–112
97. Wang WH, Wang HL. Fulminant adenovirus hepatitis following bone marrow transplantation. A case report and brief review of the literature. *Arch Pathol Lab Med* 2003;127(5):e246–e248
98. Arav-Boger R, Echavarría M, Forman M, Charache P, Persaud D. Clearance of adenoviral hepatitis with ribavirin therapy in a pediatric liver transplant recipient. *Pediatr Infect Dis J* 2000;19(11):1097–1100
99. Hedderwick SA, Greenon JK, McGaughey VR, Clark NM. Adenovirus cholecystitis in a patient with AIDS. *Clin Infect Dis* 1998;26(4):997–999
100. Bateman CM, Kesson AM, Shaw PJ. Pancreatitis and adenoviral infection in children after blood and marrow transplantation. *Bone Marrow Transplant* 2006;38(12): 807–811
101. Yokose N, Hirakawa T, Inokuchi K. Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib. *Leuk Res* 2009;33(8):e106
102. Akiyama H, Kurosu T, Sakashita C, et al. Adenovirus is a key pathogen in hemorrhagic cystitis associated with bone marrow transplantation. *Clin Infect Dis* 2001;32(9):1325–1330
103. Teramura T, Naya M, Yoshihara T, Kanoh G, Morimoto A, Imashuku S. Adenoviral infection in hematopoietic stem cell transplantation: early diagnosis with quantitative detection of the viral genome in serum and urine. *Bone Marrow Transplant* 2004;33(1):87–92
104. Miyamura K, Hamaguchi M, Taji H, et al. Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors. *Bone Marrow Transplant* 2000; 25(5):545–548
105. Fanourgiakis P, Georgala A, Vekemans M, et al. Intravesical instillation of cidofovir in the treatment of hemorrhagic cystitis caused by adenovirus type 11 in a bone marrow transplant recipient. *Clin Infect Dis* 2005;40(1): 199–201
106. Hofland CA, Eron LJ, Washecka RM. Hemorrhagic adenovirus cystitis after renal transplantation. *Transplant Proc* 2004;36(10):3025–3027
107. Ferreira GF, Oliveira RA, Lucon M, et al. Hemorrhagic cystitis secondary to adenovirus or herpes simplex virus infection following renal transplantation: four case reports. *Transplant Proc* 2009;41(10):4416–4419
108. Yagisawa T, Nakada T, Takahashi K, Toma H, Ota K, Yaguchi H. Acute hemorrhagic cystitis caused by adenovirus after kidney transplantation. *Urol Int* 1995;54(3):142–146
109. Keswani M, Moudgil A. Adenovirus-associated hemorrhagic cystitis in a pediatric renal transplant recipient. *Pediatr Transplant* 2007;11(5):568–571
110. Koga S, Shindo K, Matsuya F, Hori T, Kanda S, Kanetake H. Acute hemorrhagic cystitis caused by adenovirus following renal transplantation: review of the literature. *J Urol* 1993;149(4):838–839
111. Bruno B, Zager RA, Boeckh MJ, et al. Adenovirus nephritis in hematopoietic stem-cell transplantation. *Transplantation* 2004;77(7):1049–1057
112. Ito M, Hirabayashi N, Uno Y, Nakayama A, Asai J. Necrotizing tubulointerstitial nephritis associated with adenovirus infection. *Hum Pathol* 1991;22(12):1225–1231
113. Mori K, Yoshihara T, Nishimura Y, et al. Acute renal failure due to adenovirus-associated obstructive uropathy and necrotizing tubulointerstitial nephritis in a bone marrow transplant recipient. *Bone Marrow Transplant* 2003;31(12):1173–1176
114. Sujeet K, Vasudev B, Desai P, et al. Acute kidney injury requiring dialysis secondary to adenovirus nephritis in renal transplant recipient. *Transpl Infect Dis* 2011;13(2):174–177
115. Ardehali H, Volmar K, Roberts C, Forman M, Becker LC. Fatal disseminated adenoviral infection in a renal transplant patient. *Transplantation* 2001;71(7):998–999
116. Echavarría M, Forman M, van Tol MJ, Vossen JM, Charache P, Kroes AC. Prediction of severe disseminated adenovirus infection by serum PCR. *Lancet* 2001;358(9279):384–385
117. Sivaprakasam P, Carr TF, Coussons M, et al. Improved outcome from invasive adenovirus infection in pediatric patients after hemopoietic stem cell transplantation using intensive clinical surveillance and early intervention. *J Pediatr Hematol Oncol* 2007;29(2):81–85

118. Robin M, Marque-Juillet S, Scieux C, et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. *Haematologica* 2007;92(9):1254–1257
119. Kroes AC, de Klerk EP, Lankester AC, et al. Sequential emergence of multiple adenovirus serotypes after pediatric stem cell transplantation. *J Clin Virol* 2007;38(4):341–347
120. de Mezerville MH, Tellier R, Richardson S, Hébert D, Doyle J, Allen U. Adenoviral infections in pediatric transplant recipients: a hospital-based study. *Pediatr Infect Dis J* 2006;25(9):815–818
121. Venard V, Carret A, Corsaro D, Bordigoni P, Le Faou A. Genotyping of adenoviruses isolated in an outbreak in a bone marrow transplant unit shows that diverse strains are involved. *J Hosp Infect* 2000;44(1):71–74
122. Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2001;7(7):388–394
123. Bowles NE, Ni J, Kearney DL, et al. Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults. *J Am Coll Cardiol* 2003;42(3):466–472
124. Kelsey DS. Adenovirus meningoencephalitis. *Pediatrics* 1978;61(2):291–293
125. Ladisch S, Lovejoy FH, Hierholzer JC, et al. Extrapulmonary manifestations of adenovirus type 7 pneumonia simulating Reye syndrome and the possible role of an adenovirus toxin. *J Pediatr* 1979;95(3):348–355
126. Gray GC, McCarthy T, Lebeck MG, et al. Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004–2006. *Clin Infect Dis* 2007;45(9):1120–1131
127. Melón S, Méndez S, Iglesias B, et al. Involvement of adenovirus in clinical mononucleosis-like syndromes in young children. *Eur J Clin Microbiol Infect Dis* 2005;24(5):314–318
128. Couroucli XI, Welty SE, Ramsay PL, et al. Detection of microorganisms in the tracheal aspirates of preterm infants by polymerase chain reaction: association of adenovirus infection with bronchopulmonary dysplasia. *Pediatr Res* 2000;47(2):225–232
129. Guarner J, de Leon-Bojorge B, Lopez-Corella E, et al. Intestinal intussusception associated with adenovirus infection in Mexican children. *Am J Clin Pathol* 2003;120(6):845–850
130. Bajanowski T, Wiegand P, Cecchi R, et al. Detection and significance of adenoviruses in cases of sudden infant death. *Virchows Arch* 1996;428(2):113–118
131. Top FH Jr. Control of adenovirus acute respiratory disease in U.S. army trainees. *Yale J Biol Med* 1975;48(3):185–195
132. Barraza EM, Ludwig SL, Gaydos JC, Brundage JF. Reemergence of adenovirus type 4 acute respiratory disease in military trainees: report of an outbreak during a lapse in vaccination. *J Infect Dis* 1999;179(6):1531–1533
133. Hendrix RM, Lindner JL, Benton FR, et al. Large, persistent epidemic of adenovirus type 4-associated acute respiratory disease in U.S. army trainees. *Emerg Infect Dis* 1999;5(6):798–801
134. Gray GC, Goswami PR, Malasig MD, et al; For the Adenovirus Surveillance Group. Adult adenovirus infections: loss of orphaned vaccines precipitates military respiratory disease epidemics. *Clin Infect Dis* 2000;31(3):663–670
135. Leen AM, Rooney CM. Adenovirus as an emerging pathogen in immunocompromised patients. *Br J Haematol* 2005;128(2):135–144
136. Baldwin A, Kingman H, Darville M, et al. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. *Bone Marrow Transplant* 2000;26(12):1333–1338
137. La Rosa AM, Champlin RE, Mirza N, et al. Adenovirus infections in adult recipients of blood and marrow transplants. *Clin Infect Dis* 2001;32(6):871–876
138. Yusuf U, Hale GA, Carr J, et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. *Transplantation* 2006;81(10):1398–1404
139. Leruez-Ville M, Minard V, Lacaille F, et al. Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection. *Clin Infect Dis* 2004;38(1):45–52
140. Runde V, Ross S, Trenchel R, et al. Adenoviral infection after allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a prospective multi center surveillance study. *Bone Marrow Transplant* 2001;28(1):51–57
141. Muller WJ, Levin MJ, Shin YK, et al. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. *Clin Infect Dis* 2005;41(12):1812–1816
142. Lankester AC, van Tol MJ, Claas EC, Vossen JM, Kroes AC. Quantification of adenovirus DNA in plasma for management of infection in stem cell graft recipients. *Clin Infect Dis* 2002;34(6):864–867
143. Schilham MW, Claas EC, van Zaane W, et al. High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. *Clin Infect Dis* 2002;35(5):526–532
144. Humar A, Kumar D, Mazzulli T, et al; PV16000 Study Group. A surveillance study of adenovirus infection in adult solid organ transplant recipients. *Am J Transplant* 2005;5(10):2555–2559
145. Michaels MG, Green M, Wald ER, Starzl TE. Adenovirus infection in pediatric liver transplant recipients. *J Infect Dis* 1992;165(1):170–174
146. McGrath D, Falagas ME, Freeman R, et al. Adenovirus infection in adult orthotopic liver transplant recipients: incidence and clinical significance. *J Infect Dis* 1998;177(2):459–462
147. Bridges ND, Spray TL, Collins MH, Bowles NE, Towbin JA. Adenovirus infection in the lung results in graft failure after lung transplantation. *J Thorac Cardiovasc Surg* 1998;116(4):617–623
148. McLaughlin GE, Delis S, Kashimawo L, et al. Adenovirus infection in pediatric liver and intestinal transplant recipients: utility of DNA detection by PCR. *Am J Transplant* 2003;3(2):224–228
149. Ohori NP, Michaels MG, Jaffe R, Williams P, Yousem SA. Adenovirus pneumonia in lung transplant recipients. *Hum Pathol* 1995;26(10):1073–1079
150. Moulik M, Breinholt JP, Dreyer WJ, et al. Viral endomyocardial infection is an independent predictor and potentially treatable risk factor for graft loss and coronary vasculopathy in pediatric cardiac transplant recipients. *J Am Coll Cardiol* 2010;56(7):582–592

151. Shirali GS, Ni J, Chinnock RE, et al. Association of viral genome with graft loss in children after cardiac transplantation. *N Engl J Med* 2001;344(20):1498–1503
152. Schowengerdt KO, Ni J, Denfield SW, et al. Diagnosis, surveillance, and epidemiologic evaluation of viral infections in pediatric cardiac transplant recipients with the use of the polymerase chain reaction. *J Heart Lung Transplant* 1996; 15(2):111–123
153. Simsir A, Greenebaum E, Nuovo G, Schulman LL. Late fatal adenovirus pneumonitis in a lung transplant recipient. *Transplantation* 1998;65(4):592–594
154. Khoo SH, Bailey AS, de Jong JC, Mandal BK. Adenovirus infections in human immunodeficiency virus-positive patients: clinical features and molecular epidemiology. *J Infect Dis* 1995;172(3):629–637
155. Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. *Medicine (Baltimore)* 2006;85(4): 193–202
156. Baum S. Adenovirus. In: Mandell GL, Bennett JE, Dolin R eds. *Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases*. 6th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2005:1835–1841
157. Centers for Disease Control and Prevention (CDC). Acute respiratory disease associated with adenovirus serotype 14—four states, 2006–2007. *MMWR Morb Mortal Wkly Rep* 2007;56(45):1181–1184
158. Esposito DH, Gardner TJ, Schneider E, et al. Outbreak of pneumonia associated with emergent human adenovirus serotype 14—Southeast Alaska, 2008. *J Infect Dis* 2010; 202(2):214–222
159. Chmielewicz B, Benzler J, Pauli G, Krause G, Bergmann F, Schweiger B. Respiratory disease caused by a species B2 adenovirus in a military camp in Turkey. *J Med Virol* 2005;77(2):232–237
160. Kajon AE, Mistchenko AS, Videla C, Hortal M, Wadell G, Avendaño LF. Molecular epidemiology of adenovirus acute lower respiratory infections of children in the south cone of South America (1991–1994). *J Med Virol* 1996;48(2): 151–156
161. Elnifro EM, Cooper RJ, Klapper PE, Bailey AS, Tullo AB. Diagnosis of viral and chlamydial keratoconjunctivitis: which laboratory test? *Br J Ophthalmol* 1999;83(5): 622–627
162. Uhnoo I, Wadell G, Svensson L, Johansson ME. Importance of enteric adenoviruses 40 and 41 in acute gastroenteritis in infants and young children. *J Clin Microbiol* 1984;20(3): 365–372
163. Wold W, Horwitz M. Adenoviruses. In: Knipe DM, Howley PM, eds. *Fields Virology*. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2007:2395–2436
164. Suparno C, Milligan DW, Moss PA, Mautner V. Adenovirus infections in stem cell transplant recipients: recent developments in understanding of pathogenesis, diagnosis and management. *Leuk Lymphoma* 2004;45(5):873–885
165. van Kraaij MG, van Elden LJ, van Loon AM, et al. Frequent detection of respiratory viruses in adult recipients of stem cell transplants with the use of real-time polymerase chain reaction, compared with viral culture. *Clin Infect Dis* 2005;40(5):662–669
166. Wallot MA, Dohna-Schwake C, Auth M, et al. Disseminated adenovirus infection with respiratory failure in pediatric liver transplant recipients: impact of intravenous cidofovir and inhaled nitric oxide. *Pediatr Transplant* 2006; 10(1):121–127
167. Echavarría M, Maldonado D, Elbert G, Videla C, Rappaport R, Carballal G. Use of PCR to demonstrate presence of adenovirus species B, C, or F as well as coinfection with two adenovirus species in children with flu-like symptoms. *J Clin Microbiol* 2006;44(2):625–627
168. Adhikary AK, Inada T, Banik U, Numaga J, Okabe N. Identification of subgenus C adenoviruses by fiber-based multiplex PCR. *J Clin Microbiol* 2004;42(2):670–673
169. Kajon AE, Erdman DD. Assessment of genetic variability among subspecies b1 human adenoviruses for molecular epidemiology studies. *Methods Mol Med* 2007;131:335–355
170. Xu W, Erdman DD. Type-specific identification of human adenovirus 3, 7, and 21 by a multiplex PCR assay. *J Med Virol* 2001;64(4):537–542
171. Li QG, Wadell G. Analysis of 15 different genome types of adenovirus type 7 isolated on five continents. *J Virol* 1986; 60(1):331–335
172. Wang H, Tuve S, Erdman DD, Lieber A. Receptor usage of a newly emergent adenovirus type 14. *Virology* 2009;387(2): 436–441
173. Gaggar A, Shayakhmetov DM, Liszewski MK, Atkinson JP, Lieber A. Localization of regions in CD46 that interact with adenovirus. *J Virol* 2005;79(12):7503–7513
174. Yamadera S, Yamashita K, Akatsuka M, Kato N, Inouye S. Trend of adenovirus type 7 infection, an emerging disease in Japan: a report of the National Epidemiological Surveillance of Infectious Agents in Japan. *Jpn J Med Sci Biol* 1998;51(1): 43–51
175. Azar R, Varsano N, Mileguir F, Mendelson E. Molecular epidemiology of adenovirus type 7 in Israel: identification of two new genome types, Ad7k and Ad7d2. *J Med Virol* 1998;54(4):291–299
176. Wadell G, Cooney MK, da Costa Linhares A, et al. Molecular epidemiology of adenoviruses: global distribution of adenovirus 7 genome types. *J Clin Microbiol* 1985;21(3): 403–408
177. Metzgar D, Osuna M, Yingst S, et al. PCR analysis of Egyptian respiratory adenovirus isolates, including identification of species, serotypes, and coinfections. *J Clin Microbiol* 2005;43(11):5743–5752
178. Kajon AE, Wadell G. Molecular epidemiology of adenoviruses associated with acute lower respiratory disease of children in Buenos Aires, Argentina (1984–1988). *J Med Virol* 1992;36(4):292–297
179. Piedra PA, Poveda GA, Ramsey B, McCoy K, Hiatt PW. Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. *Pediatrics* 1998;101(6):1013–1019
180. Cooper RJ, Hallett R, Tullo AB, Klapper PE. The epidemiology of adenovirus infections in Greater Manchester, UK 1982–96. *Epidemiol Infect* 2000;125(2):333–345
181. Kim YJ, Hong JY, Lee HJ, et al. Genome type analysis of adenovirus types 3 and 7 isolated during successive outbreaks of lower respiratory tract infections in children. *J Clin Microbiol* 2003;41(10):4594–4599
182. Metzgar D, Osuna M, Kajon AE, Hawksworth AW, Irvine M, Russell KL. Abrupt emergence of diverse species B adenoviruses at US military recruit training centers. *J Infect Dis* 2007;196(10):1465–1473



183. Noda M, Yoshida T, Sakaguchi T, Ikeda Y, Yamaoka K, Ogino T. Molecular and epidemiological analyses of human adenovirus type 7 strains isolated from the 1995 nationwide outbreak in Japan. *J Clin Microbiol* 2002;40(1):140–145
184. Murtagh P, Cerqueira C, Halac A, Avila M, Kajon A. Adenovirus type 7h respiratory infections: a report of 29 cases of acute lower respiratory disease. *Acta Paediatr* 1993;82(6-7):557–561
185. Li QG, Wadell G. Comparison of 17 genome types of adenovirus type 3 identified among strains recovered from six continents. *J Clin Microbiol* 1988;26(5):1009–1015
186. Adrian T, Best B, Hierholzer JC, Wigand R. Molecular epidemiology and restriction site mapping of adenovirus type 3 genome types. *J Clin Microbiol* 1989;27(6):1329–1334
187. Landry ML, Lebeck MG, Capuano AW, McCarthy T, Gray GC. Adenovirus type 3 outbreak in Connecticut associated with a novel variant. *J Med Virol* 2009;81(8):1380–1384
188. Rebelo-de-Andrade H, Pereira C, Gíria M, et al. Outbreak of acute respiratory infection among infants in Lisbon, Portugal, caused by human adenovirus serotype 3 and a new 7/3 recombinant strain. *J Clin Microbiol* 2010;48(4):1391–1396
189. Kandel R, Srinivasan A, D'Agata EM, Lu X, Erdman D, Jung M. Outbreak of adenovirus type 4 infection in a long-term care facility for the elderly. *Infect Control Hosp Epidemiol* 2010;31(7):755–757
190. Top FH Jr, Buescher EL, Bancroft WH, Russell PK. Immunization with live types 7 and 4 adenovirus vaccines, II: Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. *J Infect Dis* 1971;124(2):155–160
191. Top FH Jr, Grossman RA, Bartelloni PJ, et al. Immunization with live types 7 and 4 adenovirus vaccines, I: Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. *J Infect Dis* 1971;124(2):148–154
192. Choi EH, Kim HS, Eun BW, et al. Adenovirus type 7 peptide diversity during outbreak, Korea, 1995–2000. *Emerg Infect Dis* 2005;11(5):649–654
193. Cho CT, Hiatt WO, Behbehani AM. Pneumonia and massive pleural effusion associated with adenovirus type 7. *Am J Dis Child* 1973;126(1):92–94
194. Brown RS, Nogrady MB, Spence L, Wiglesworth FW. An outbreak of adenovirus type 7 infection in children in Montreal. *Can Med Assoc J* 1973;108(4):434–439
195. Wadell G, Varsányi TM, Lord A, Sutton RN. Epidemic outbreaks of adenovirus 7 with special reference to the pathogenicity of adenovirus genome type 7b. *Am J Epidemiol* 1980;112(5):619–628
196. Centers for Disease Control (CDC). Adenovirus type 7 outbreak in a pediatric chronic-care facility—Pennsylvania, 1982. *MMWR Morb Mortal Wkly Rep* 1983;32(19):258–260
197. Kajon A, Wadell G. Genome analysis of South American adenovirus strains of serotype 7 collected over a 7-year period. *J Clin Microbiol* 1994;32(9):2321–2323
198. de Silva LM, Colditz P, Wadell G. Adenovirus type 7 infections in children in New South Wales, Australia. *J Med Virol* 1989;29(1):28–32
199. Straube RC, Thompson MA, Van Dyke RB, et al. Adenovirus type 7b in a children's hospital. *J Infect Dis* 1983;147(5):814–819
200. Sakata H, Taketazu G, Nagaya K, et al. Outbreak of severe infection due to adenovirus type 7 in a paediatric ward in Japan. *J Hosp Infect* 1998;39(3):207–211
201. Asim M, Chong-Lopez A, Nickelleit V. Adenovirus infection of a renal allograft. *Am J Kidney Dis* 2003;41(3):696–701
202. Kendall EJ, Riddle RW, Tuck HA, Rodan KS, Andrews BE, McDonald JC. Pharyngo-conjunctival fever; school outbreaks in England during the summer of 1955 associated with adenovirus types 3, 7, and 14. *BMJ* 1957;2(5037):131–136
203. Tate JE, Bunning ML, Lott L, et al. Outbreak of severe respiratory disease associated with emergent human adenovirus serotype 14 at a US air force training facility in 2007. *J Infect Dis* 2009;199(10):1419–1426
204. Lewis PF, Schmidt MA, Lu X, et al. A community-based outbreak of severe respiratory illness caused by human adenovirus serotype 14. *J Infect Dis* 2009;199(10):1427–1434
205. Van Der Veen J, Dijkman JH. Association of type 21 adenovirus with acute respiratory illness in military recruits. *Am J Hyg* 1962;76:149–159
206. van der Avoort HG, Adrian T, Wigand R, Wermenbol AG, Zomerdijk TP, de Jong JC. Molecular epidemiology of adenovirus type 21 in the Netherlands and the Federal Republic of Germany from 1960 to 1985. *J Clin Microbiol* 1986;24(6):1084–1088
207. Larsen RA, Jacobson JT, Jacobson JA, Strikas RA, Hierholzer JC. Hospital-associated epidemic of pharyngitis and conjunctivitis caused by adenovirus (21/H21 + 35). *J Infect Dis* 1986;154(4):706–709
208. Becroft DM. Bronchiolitis obliterans, bronchiectasis, and other sequelae of adenovirus type 21 infection in young children. *J Clin Pathol* 1971;24(1):72–82
209. Shult PA, Polyak F, Dick EC, Warshauer DM, King LA, Mandel AD. Adenovirus 21 infection in an isolated Antarctic station: transmission of the virus and susceptibility of the population. *Am J Epidemiol* 1991;133(6):599–607
210. Seidemann K, Heim A, Pfister ED, et al. Monitoring of adenovirus infection in pediatric transplant recipients by quantitative PCR: report of six cases and review of the literature. *Am J Transplant* 2004;4(12):2102–2108
211. Kampmann B, Cubitt D, Walls T, et al. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. *Br J Haematol* 2005;130(4):595–603
212. Leruez-Ville M, Chardin-Ouachée M, Neven B, et al. Description of an adenovirus A31 outbreak in a paediatric haematology unit. *Bone Marrow Transplant* 2006;38(1):23–28
213. Slatter MA, Read S, Taylor CE, et al. Adenovirus type F subtype 41 causing disseminated disease following bone marrow transplantation for immunodeficiency. *J Clin Microbiol* 2005;43(3):1462–1464
214. Erard V, Huang ML, Ferrenberg J, et al. Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease. *Clin Infect Dis* 2007;45(8):958–965
215. Lankester AC, Heemskerk B, Claas EC, et al. Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection. *Clin Infect Dis* 2004;38(11):1521–1525

216. Gavin PJ, Katz BZ. Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. *Pediatrics* 2002;110(1 Pt 1):e9
217. Morfin F, Dupuis-Girod S, Mundweiler S, et al. In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. *Antivir Ther* 2005;10(2):225–229
218. Naesens L, Lenaerts L, Andrei G, et al. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. *Antimicrob Agents Chemother* 2005;49(3):1010–1016
219. Doan ML, Mallory GB, Kaplan SL, et al. Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients. *J Heart Lung Transplant* 2007;26(9):883–889
220. Ljungman P, Ribaud P, Eyrich M, et al; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant* 2003;31(6):481–486
221. Legrand F, Berrebi D, Houhou N, et al. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. *Bone Marrow Transplant* 2001;27(6):621–626
222. Nagafuji K, Aoki K, Henzan H, et al. Cidofovir for treating adenoviral hemorrhagic cystitis in hematopoietic stem cell transplant recipients. *Bone Marrow Transplant* 2004;34(10):909–914
223. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. *Blood* 2002;100(5):1619–1627
224. Heemskerk B, Lankester AC, van Vreeswijk T, et al. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. *J Infect Dis* 2005;191(4):520–530
225. van Tol MJ, Claas EC, Heemskerk B, et al. Adenovirus infection in children after allogeneic stem cell transplantation: diagnosis, treatment and immunity. *Bone Marrow Transplant* 2005;35(Suppl 1):S73–S76
226. Binn LN, Sanchez JL, Gaydos JC. Emergence of adenovirus type 14 in US military recruits—a new challenge. *J Infect Dis* 2007;196(10):1436–1437